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 Abstract 
 
The International Agency for Research on Cancer indicated that cancer burden was raised in 2012 to 
14.1 million incidence cases and 8.2 mortality cases. Consequently, novel approaches are urgently 
required for further improvement in existing cancer therapies. Synthesis of the pyridine ring system 
and its derivatives occupy an important place in the realm of synthetic organic chemistry, due to their 
therapeutic and pharmacological properties. The current study investigated the anti-cancer activity of 
novel pyridine derivatives. Twenty novel Pyridine Derivatives were screened using WST-1 assay on 
several cell lines to assess their toxicity and to determine whether the effect is tumor or cell type 
specific. Dose response curves were obtained for compound 9a for further investigations. Detection of 
apoptosis and cell cycle checkpoint analysis was done using flow cytometry and expression of several 
apoptotic and anti-apoptotic proteins was carried out by Western Blot. Initial screening revealed that 
100µM treatment with pyridine derivatives for the above mentioned cell lines for 24 hours suppressed 
the viability as follows: compound 9a reduced the viability by 40% in MCF-7 cells and by 45% in 
HCT-116, compound 7b reduced the viability in SKOV-3 by 35% and finally compound 11 
suppressed the viability of SKOV-3 by 44%. Compound 9a induced growth inhibition in MCF-7 cells 
and resulted in the induction of apoptosis with an IC50 of 20µM. It upregulated the expression of p53, 
Bax and Caspase-3 in MCF-7 cells. In addition, it caused significant down-regulation of Bcl-2, Mdm-2 
and Akt. Compound 9a exhibited less toxicity on non-tumorigenic breast epithelial cell line MCF-12a. 
Findings of the study indicated that compound 9a possesses potent anti-proliferative activity against 
MCF-7 cells and could be a promising chemotherapeutic agent with less toxicity on non-tumorigenic 
cells. Further screening and investigating molecular mechanisms of this potent agent on other cancer 
cell lines is highly required. 
 
TABLE OF CONTENTS 
 
SUBJECT PAGE 
        
1. Introduction       
2. Literature Survey  
2.1.Cancer Background  
2.2.Cancer Statistics 
2.2.1. Worldwide Statistics 
2.2.2. Qatar Cancer Registry         
2.3.Chemotherapeutic Agents 
2.4.Chemotherapeutic Agents & Apoptosis 
2.5.Pyridine  
1.5.1. Chemical Properties 
1.5.2. Pyridine Derivatives 
1.5.3. Cyanopyridine 
2.6.Pyridine Derivatives and Apoptosis  
1-2 
 
3 
3 
3-5 
5-6 
7-8 
8-14 
 
14-15 
15-18 
18-19 
19-20 
3. Materials 
3.1.Table 1: Pyridine Derivatives 
3.2.Table 2: Cell Lines  
3.3.Table 3: Chemicals used for Cell Culture  
3.4.Table 4: Chemicals used for Cell proliferation Assay 
3.5.Table 5: Chemicals used for Flow Cytometry Analysis 
3.6.Table 6: Chemicals used for Western Blot  
 
21-25 
26 
26 
26 
27 
27 
4. Methods 
4.1. Cell Line and Cell Culture 
4.2. Cell Count Using Hemacytometer 
4.3. Drug Stock Preparation 
4.4. Cell Viability Assay WST-1 Assay 
4.5. Morphological Examination 
4.6. Dose Response Curve 
 
28-31 
31 
31 
32 
34 
34 
4.7. Flow Cytometry 
4.7.1. Cell Cycle Analysis 
4.7.2. Apoptosis Detection Annexin-V 
4.8. Western Blot 
35 
35 
36 
37 
5. Results 
5.1. Cell Viability 
5.2. Potent Pyridine Derivatives  
5.3. Compound 9a and MCF-7 cells 
5.4. Morphological Appearance of MCF-7 Cells with Compound 9a 
5.5. Dose Response Curve and IC50 of Compound 9a 
5.6. Cytotoxicity of Compound 9a on Non-Tumorigenic Breast Epithelial 
Cells MCF-12a and Statistical Analysis 
5.7. Apoptosis Detection Assay Annexin-V FITC 
5.8. Cell Cycle Analysis 
5.9. Impact of 9a on Apoptotic and Survival Signals 
6. Discussion  
7. Conclusion and Recommendations  
8. References  
9. Arabic Abstract and Summary  
 
38-42 
43 
43 
44-46 
47-48 
49 
 
54-56 
57-58 
58-61 
62-69 
70 
71-72 
73-78 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LIST OF FIGURES 
 
Item Title Page 
 
Figure 2.4.1 
 
Pathway of Chemotherapeutic Agents in Inducing Apoptosis 10 
Figure 2.4.2 Apoptotic Pathway – Intrinsic and Extrinsic Pathways 
 
14 
Figure 2.5.1 Pyridine Ring 
 
15 
Figure 3.1 Selected Cancer Cell Lines Screened in the Study 
 
31-32 
Figure 3.2 TPEN Structure 
 
33 
Figure 5.1.1 Cell Viability of MCF-7 cells after Treatment with 100µM of 20 
Pyridine Derivatives for 24hours  
 
40 
Figure 5.1.2 Cell Viability of MDA-MB-231 cells after Treatment with 100µM of 
20 Pyridine Derivatives for 24hours  
 
41 
Figure 5.1.3 Cell Viability of HCT-116 cells after Treatment with 100µM of 20 
Pyridine Derivatives for 24hours  
 
42 
Figure 5.1.4 Cell Viability of SKOV-3 cells after Treatment with 100µM of 20 
Pyridine Derivatives for 24hours  
 
43 
Figure 5.1.5 Cell Viability of OVCAR cells after Treatment with 100µM of 20 
Pyridine Derivatives for 24hours  
 
44 
Figure 5.3.1 Compound 9a Structure  45 
 
Figure 5.3.2 3D Structure of Compound 9a 46 
 
Figure 5.4.1 The morphological appearance of MCF-7 cells after treatment with 
0.5, 1, 5, 20, 50 and 100uM of compound 9a for 24h 
 
48 
Figure 5.4.2 The morphological appearance of MCF-7 cells after treatment with 
0.5, 1, 5, 20, 50 and 100uM of TPEN for 24h 
 
49 
Figure 5.5.1 Dose Response Curve for compound 9a on MCF-7 cells 50 
 
Figure 5.5.1 Dose Response Curve of TPEN on MCF-7 cells 51 
 
Figure 5.6.1 Cytotoxicity of compound 9a on MCF-7 and MCF-12a 52 
 
Figure 5.6.2 Q-Q plot for MCF-7 and MCF-12A  
 
54 
Figure 5.7.1 Compound 9a induces apoptosis in MCF-7 cells using Annexin-V 
Apoptotic Detection Assay 
56 
 
 
Figure 5.7.2 TPEN induces apoptosis in MCF-7 cells using Annexin-V Apoptotic 
Detection Assay 
 
57 
Figure 5.7.3 3D Orientation Structure of Apoptotic Detection Assay 58 
 
Figure 5.7.4 Histogram Representing Late Apoptotic Phase 59 
 
Figure 5.8.1 Cell Cycle Analysis of untreated MCF-7 cells 60 
 
Figure 5.8.2 Cell Cycle Analysis of treated MCF-7 cells 61 
 
Figure 5.9.1 Western Blot Assay for p53, p21 and Bax 62 
 
Figure 5.9.2 Western Blot Assay for bcl-2, Mdm-2 and Akt 63 
 
Figure 5.9.3. 
 
Western Blot Assay for caspase-3 and pro-caspase-3 
 
64 
 
 
  
LIST OF TABLES 
 
Item Title Page 
 
2.2.2 Cancer cases in the State of Qatar 2012 6 
3.1 Pyridine Derivatives 23-27 
3.2 Cell Lines 28 
3.3 Chemicals used for Cell Proliferation Assay 28 
3.4 Chemicals used for Cell Culture 28 
3.5 Chemicals used for Flow Cytometry Analysis 29 
3.6 Chemicals used for Western Blot Analysis 29 
5.1 Potent Pyridine Derivatives 46 
5.2 Testing Normality in MCF-7 and MCF-12a using SPSS  53 
5.3 
 
Testing Normality in MCF-7 and MCF-12a using SPSS 
“Kolmogorov-Smirnov” and “Shapiro-Wilk” 
53 
5.4 Statistical Significance for three groups (MCF-7, MCF-12a and 
control) using Kruskal Wallis method 
55 
5.5 
 
Statistical Significance for two groups (MCF-7, MCF-12a) using 
Mann-Whitney U method 
55 
 
  
LIST OF ABBREVIATIONS 
 
Abbreviation Explanation 
 
AFP Alpha Feto Protein 
DMSO Dimethyl Sulfoxide  
FBS Feto Bovine Serum 
DMEM Dulbecco’s Modified Eagle’s Medium 
IAP Inhibitor of Apoptosis 
IARC International Agency of Cancer Research 
RPMI Roswell Park Memorial Institute Medium 
PBS Phosphate Buffered Saline 
PI Propidium Iodide 
TTBS Tris-Buffered Saline 
TPEN  (N,N,N′,N′-Tetrakis (2-pyridylmethyl) ethylenediamine) 
WHO World Health Organization 
K-S test Kolmogorov-Smirnov 
SPSS Statistical Package for the Social Sciences 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Declaration 
 
 
 
I declare that this dissertation is my own original work has not been previously submitted for any 
degree in any other university. All the sources I have used or quoted have been indicated and 
acknowledged. 
 
 
 
Mona O. M. Mohsen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Acknowledgment 
 
Immeasurable appreciation and deepest gratitude for the support and help are extended to the 
following persons who assist me and contribute in making this study possible: 
 
Dr. Ahmed Malki, my advisor for his support, advice, suggestions, valuable comments and provisions 
that benefited me in the completion and success of my study, who shared his knowledge and helped in 
the analysis of the data. His guidance helped me during my research and writing of this thesis. I could 
not have imagined having a better advisor and mentor for my Master study.  
 
Prof. Khaled Machaca, for his generous support, encouragement, coaching and insightful comments. I 
am obliged to staff members in the Machaca Lab for the valuable information they provided in their 
respective fields. I am grateful for their cooperation during the period of my project. 
 
Dr. Hassan Aziz, for his patience, motivation and enthusiasm in this project. I also take this 
opportunity to express a deep sense of gratitude to his cordial support, valuable information and 
guidance, which helped me in completing this task through various stages. 
 
A special word of thanks to Prof. Alexander Knuth and Dr. Abdel-Salam Gomaa who supported me 
throughout the project. 
 
Last and not least, I would like to thank my father for supporting me spiritually throughout my life and 
my friends who were beside me in each step of conducting my Master degree.  
 
 
 
 
 
 
 
 
 
 
 
1 
 
1. Introduction: 
 
Cancer is the second leading cause of death worldwide. The International Agency for Research on 
Cancer indicated that the burden in 2012 was raised to 14.1 million incidence cases and 8.2 mortality 
cases (Siegel, 2013) . In the State of Qatar cancer accounts for 10% of all deaths (Qatar Cancer 
Registry, 2014). Qatar has a young population at present, whilst in 2010 the proportion of the 
population over 60 was just 2%, by 2050 this will increase to 20%. An ageing and growing population 
mean the incidence of cancer in Qatar will double by 2030 (Qatar Cancer Registry, 2014). The 
National Cancer Strategy was launched in 2011 with the goal that Qatar would become a world-
renowned center of excellence in cancer research and care. Best practice in cancer treatment is 
constantly evolving as new research breakthroughs, this means the development of novel therapies that 
bring new treatment options to Qatar patients. Consequently, novel approaches are urgently required 
for further improvement in existing cancer therapies and for treating those cancers for which there are 
as yet no effective therapies. Synthesis of the pyridine ring system and its derivatives occupy an 
important place in the realm of synthetic organic chemistry, due to their therapeutic and 
pharmacological properties (Srivastava et al., 2007). They have emerged as integral backbones of over 
7000 existing drugs. In the last few years, particular interest has been focused on 3-cyano-2(1H)-
pyridone and its derivatives due to their wide range of practical uses as medicinal compounds. 3-
cyanopyridines with different alkyl or aryl/heteroaryl groups were found to possess anti-cancer 
activity (Davari, 2014). Careful literature survey revealed that incorporation of alkoxy substituents 
(methoxy and/or aryloxy moieties) results in significant enhancement of several biological activities 
due to magnification of compounds' lipophilicity (Deslandes et al., 2012).  
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Hypothesis:  
Based on previous studies of anticancer activities of pyridine derivatives, the current study attempts to 
identify novel and potent pyridine derivatives with minimal toxicity to non-tumorigenic counterparts. 
 
Accordingly, this research aims to:  
• Screen novel pyridine derivatives for anti-cancer activity against different cancer cell lines and 
select effective derivatives 
• Test the effective derivative against non-tumorigenic counterparts for cytotoxicity 
• Investigate the apoptotic and molecular mechanism of the potent derivatives  
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2. Literature Survey: 
 
2.1.Cancer Background 
Cancer is defined as the uncontrolled growth and metastasis of abnormally dividing cells beyond their 
boundaries; however, it is a complex class of disease triggered by expression and structural 
abnormalities of the coding and non-coding genes (Hanahan, 2011).  
 
Hanahan and Weinberg (2011) argued that cancer shares some hallmarks acquired during the 
development of human neoplasms. The first six biological capabilities of tumor cells that rationalize 
the complexity of cancer are sustaining proliferative signaling, irresponsiveness to negative signaling, 
evading apoptosis, inducing angiogenesis, replicative immortality and the ability to invade and 
metastasize to other tissues. Three emerging hallmarks were added to the existing ones: genome 
instability is responsible for the genetic diversity in cancer; the reprogramming of the metabolic 
profile of cancerous cells; and the ability to evade the immune system. In addition to the above listed 
hallmarks, the ability of tumor cells to create a special environment called “Tumor Environment” adds 
to the complexity of cancer. “Recognition of the widespread applicability of these concepts will 
increasingly affect the development of new means to treat human cancer” (Hanahan, 2011).  
 
2.2. Cancer Statistics 
2.2.1. Worldwide Statistics 
The International Agency for Research on Cancer (IARC) published on December 12, 2013 the latest 
data on cancer incidence and mortality for 28 types of cancers in about 184 countries worldwide 
.These statistics offer a comprehensive overview of the worldwide cancer burden. The burden in 2012 
was raised to 14.1 million incidence cases and 8.2 deaths from cancer compared with 12.7 million and 
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7.6 million in 2008 respectively (American Cancer Society, 2014).   Lung cancer was the most 
commonly diagnosed cancer worldwide accounting for (1.8 million, 13% of the total). Followed by 
breast cancer (1.7 million 11.9%) of total and colon-rectum (1.4 million 9.7%). Lung cancer caused 
the highest mortality (1.6 million, 19.4% of the total) followed by liver cancer (0.8 million, 9.1%) and 
finally stomach cancer (0.7 million, 8.8%). American Cancer Society estimated a substantive increase 
in the number of new cancer cases to 19.3 million yearly by 2025 and 24 million by 2035. This is due 
to the growth and aging of the global population (American Cancer Society, 2014).  
 
About 1.7 million women were diagnosed with breast cancer in 2012, the incidence of breast cancer 
has increased by more than 20% while mortality has also increased by 14%, in 2012 about 522,000 
deaths were recorded. Breast cancer is the most frequently diagnosed cancer among women in about 
140 countries, representing one in four of all cancers in women. The incidence of breast cancer has 
increased in most world regions but remains higher in more developed regions however the mortality 
rate is higher in less developed countries due to lack of early detection and less treatment facilities 
Approximately 232,670 new cases of invasive carcinoma in situ are expected to be diagnosed in the 
United States of America in addition to about 62,570 new cases of carcinoma in situ only in 2014 
(Siegel et al., 2013).  
 
Colorectal cancer is the third most common cancer in both men and women.  It is estimated that 
96,830 colon cancer and 40,000 rectal cancer cases will be diagnosed in the United States of America 
in 2014 (American Cancer Society, 2014).  
5 
 
Ovarian cancer is a fetal cancer ranked the eighteenth most common cancer worldwide and the seventh 
among women, In 2012 about 239, 000 cases were recorded account for about 4% of all new cancer 
cases. The risk of ovarian cancer occurs usually before menopause and increases slowly after that. It is 
usually asymptomatic at the early stages, therefore it is usually diagnosed at advanced stages, with 
approximately low survival rates 30-50% (Siegel et al., 2013).   
 
2.2.2. Qatar Cancer Registry 
The “Cancer Incidence in Five Continents; volume X (CI5-X)” published by the International Agency 
for Research on Cancer (IARC) announced that cancer is considered the third cause of death in Qatar 
after , it is expected that the burden will nearly triple over the next 20 years (Qatar Cancer Statistics, 
2014).  
 
The Supreme Council of Health has estimated that 30% of cancer related deaths are caused by 
preventable risk factors. Furthermore, the incidence of cancer has increased by 22% in 2012 compared 
to 2011 with about 7.1 cases per 100,000 population. Cancer incidence among Qataris was 10.8 cases 
per 10,000 population while for non-Qataris it was 6.5 with a higher incidence in females than males. 
The most common cancers in the State of Qatar were breast cancer accounting for 18.9% of the total 
cancer cases, followed by bone marrow cancer by 8% and colo-rectal cancer by 7.3%. Breast cancer 
cases in the State of Qatar has increased dramatically by 41% since 2011. Table 2.2.2 represents total 
cancer cases in the State of Qatar in 2012 (Supreme Council of Health, 2012).  
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Table 2.2.2: Cancer cases in the State of Qatar 2012  
 
 
 
 
The above measures were age standardized to reflect the average age-structure of all populations 
compared over the period of use; this would remove the effects of famine and historical events on the 
composition of age population. WHO new World Standard Population measures the percentage of the 
population in each 5-year age group (Qatar Cancer Statistics, 2014).   
 
This standard will be adopted widely for global comparison to facilitate the analysis of international 
comparison of sets of age-specific epidemiological and demographic rates across populations with 
different age composition, and would reduce the confusion among data users (Jemal et al., 2011). 
 
The incidence of cancer does not drop over the past years with most complicated cases in the 
developing countries, it is estimated that deaths of cancer will overcome the deaths of cardiovascular 
diseases (Siegel et al., 2013).   
 
7 
 
2.3. Chemotherapeutic Agents 
Chemotherapy refers to a group of agents act by damaging-DNA, and inducing programmed cell death 
or what is called apoptosis (Palmieri, 2013).  The origin of chemotherapy goes back to 1943 upon the 
bombing of the American warship in Bari, Italy. This incidence led to the release of a large cloud of 
mustard gas, thousands of people died, however survivors suffered from bone marrow cells depletion 
and severe anemia (Weinberg, 2014). Research on mustard gas had begun earlier in 1942 at Yale 
University when Gustaf and Gilman discovered that intravenous doses of mustard gas could cause 
significant regression in lymphoma. Furthermore, other alkylating agents were successful in treating 
glioblastomas (Weinberg, 2014).   
 
Chemotherapeutic agents can be classified according to the mode of action. For example, 
antimetabolites such as Methotrexate, 5-Flourouracil, Gemcitabine and Clardibine interfere with the 
synthesis of purines and pyrimidines in the cell and compete with the synthesis of DNA or RNA. 
Another group is the alkylating agents which form covalent bonds with different cellular components 
such as DNA. Cyclophosphamide, ifosphamide, melphalan and temozolamide are examples of 
alkylating agents (Siegel et al., 2013). Microtubule inhibitors disrupt the process of mitosis by 
interfering with the mitotic spindles and the equilibrium between polymerization and de-
polymerization. Taxanes and Vinca alkaloids are examples of this category. The last category is the 
cytotoxic antibiotics such as Doxorubicin, Dactinomycin, Epirubicin and Bleomycin (Siegel et al., 
2013). 
 
The European Organization for Research and Treatment of Cancer has graded and scored the side 
effects of the chemotherapeutic agents into acute and chronic toxicity. The acute toxicity includes 
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nausea, vomiting, diarrhea, bone marrow suppression, mucositis, alopecia, peripheral neuropathy, 
gastrointestinal disturbance, thrombocytopenia and anemia. The chronic toxicity involves pulmonary 
fibrosis, infertility, cardiac failure and secondary cancer (Palmieri, 2013).  
 
The development of Acute Myeloid Leukemia and lymphoblastic leukemia are the most common 
cancers developed after the treatment with chemotherapeutic agents. It has been found that alkylating 
agents would increase the risk of leukemia after 2 years of treatment; the leukemic cells tend to exhibit 
specific mutations with poor prognosis (Palmieri, 2013). 
 
“In addition to their cytotoxicity, these agents are highly mutagenic, leaving the genomes of exposed 
cells with hundreds if not thousands of point mutations. This reveals another side of a number of anti-
cancer treatments. In addition to their effects in reducing or eliminating tumors, x-rays and certain 
cytotoxic agents are also carcinogenic and their short-term success in producing clinical remissions 
may be counterbalanced by the appearance years later of independently arising, second site tumors that 
are consequences of their mutagenic actions” (Weinberg, 2015). Hannun (1997) has argued that the 
effectiveness of chemotherapeutic agents is significantly limited by the terrible side effects or their 
effect on normal cells.  
 
2.4. Chemotherapeutic Agents and Apoptosis 
Previous research on the chemotherapeutic agents have shown that these agents exert their anti-tumor 
activity mainly in three phases. The first phase is the interaction between the agent and its target in the 
cell through which it has been designed to exert its effect (Hannun, 1997).  
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The second phase includes the signaling transduction pathways and the third phase is the programmed 
cell death or apoptosis as illustrated in (Figure 2.4.1.). (Hannun, 1997). 
 
 
 
Figure 2.4.1. Pathway of Chemotherapeutic agents in inducing apoptosis through three phases. 
Phase I “Insult Generation” by which each chemotherapeutic agent exerts its effect– Phase II “Signal Transduction” due to 
the molecular sensors of damage and injury and finally Phase III “Decision Execution” by inducing apoptosis. 
(Hannun, 1997) 
 
 
Apoptosis is a general process that occurs in an astonishing rate in the body, billions of cells go into 
apoptosis in the bone marrow and intestine every hour and more than half of the nerve cells die after 
formation in the nervous system. The cells in the developing nervous system die by apoptosis to adjust 
the number of the nerve cells to match the target cell number required for innervation (Mattern, 2004).  
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Apoptosis has distinctive morphological features including shrinkage of the cell, condensation of the 
chromatin and blebbing of the plasma membrane. The most common characteristic of apoptosis is 
pyknosis a result of irreversible condensation of the chromatin. The apoptotic cell appears as a round 
or oval mass with condensed nuclear chromatin and dark eosinophilic cytoplasm. Blebbing of the 
plasma membrane without lysis occurs next followed by karyorrhexis, a process of cellular 
degeneration involving the fragmentation of the nucleus (Wyllie, 2010).  
 
The apoptotic bodies consist of tightly packed cytoplasmic organelles with or without nuclear 
materials, bound by a membrane. The plasma membrane in apoptotic cells remain intact presenting 
several epitopes (Wyllie, 2010). These epitopes attract phagocytes and macrophages, which will digest 
the apoptotic cells and prevent the initiation of inflammatory reaction or secondary necrosis (Elmore, 
2007).   
 
The intracellular machinery of apoptosis depends on a family of proteases that have cysteine in their 
active site and they cleave their protein targets at specific aspartic acid residues. These proteases are 
called caspases. Caspases are initially synthesized in the cell as pro-caspases or inactive precursors and 
activated by cleavage at aspartic acids or by different caspases (Golstein, 1997). 
 
This process results in activation of other pro-caspases ending in an amplifying proteolytic cascade. 
The activated cascades will then activate other proteins found in the cell such as nuclear lamina 
causing irreversible breakage of the nuclear lamina, it also cleaves a protein that holds DNA-degrading 
enzyme, allowing the cell to dismantle itself neatly and quickly. This protease cascade is a non-
destructive, self-amplifying and irreversible as well (Golstein, 1997). 
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Pro-caspases activated in the cell by binding to an adaptor protein, all nucleated cells contain pro-
caspases require an activation signal to initiate the destruction of the cell and apoptosis, the caspase 
activity is tightly regulated by the cell to control the programmed death until needed (Hotta et al., 
2003).  
 
The activation of pro-caspases is triggered by different adaptor proteins, these adaptor proteins act by 
aggregating the initiator pro-caspases in a complex. The protease activity of the initiator pro-caspases 
is small but aggregation will trigger their activation and cleave each other or cause a conformational 
change that will initiate the pro-caspase. The activated caspase within moments will act to cleave the 
downstream pro-caspase to amplify the death signal and spread out to the entire cell (Fulda, 2015).  
 
Furthermore, the activation of pro-caspase triggered from outside of the cell by activating specific cell 
surface receptors known as death receptors (Figure 2.4.2.). For example, killer lymphocytes can 
induce apoptosis when producing a specific protein called Fas ligand, this protein binds to the cell 
death receptor. Fas receptor protein on the surface of the target cell will act to recruit intracellular 
adaptor proteins bind and aggregate to pro-caspase 8 molecule, activating a downstream pro-caspases 
and inducing apoptosis (Fulda, 2015).  
 
It is known that some damaged or stressed cells will produce Fas receptor and ligand to kill themselves 
and trigger the intracellular caspase cascade. Also when cells are under stress or damage they can kill 
themselves by triggering the aggregation and activation of pro-caspases within the cell “the Intrinsic 
Pathway” as illustrated in (Figure 2.4.2.). This is mainly done when the mitochondria is induced to 
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release cytochrome c -which is the electron carrier protein- into the cytosol, this activity will result in 
the activation of an adaptor protein called Apaf-1 (Fulda, 2015).  
 
This pathway of activating the pro-caspases recruited in most forms of apoptosis leading to an 
amplifying and accelerating caspase cascade. Caspase-3 is a vital cysteine protease in the intrinsic 
apoptosis execution phase, when apoptosis is triggered caspase-3 acts by cleaving ADP-ribose 
polymerase PARP and SREBP (Fulda, 2015).  
 
 p53 is activated when DNA damage occurs in the cell, p53 will activate transcription genes that 
encode several proteins that belong to the Bcl-2 family and promote and release cytochrome c from 
the mitochondria (Fulda, 2015).  
 
Bcl-2 family proteins and IAP proteins are considered the main intracellular regulators of apoptosis 
and the cell death program as they regulate pro-caspases, however, some members of the Bcl-2 family 
such as Bcl-2 itself and Bcl-XL inhibit apoptosis as they block the release of cytochrome c from 
mitochondria. Other members of the Bcl-2 family will induce apoptosis by promoting pro-caspase cell 
death and activation, they are not considered as death inhibitors. An example of these promoters of 
cell death is Bad, which binds and inactivates the death inhibiting members of Bcl-2 family, while Bax 
and Bak will function by stimulating the release of cytochrome c from the mitochondria, Bax and Bak 
are crucial in inducing apoptosis in the cells, a mutation in the genes encoding these proteins will 
cause resistance to most apoptosis-inducing stimuli. Bax and Bak activated by Bid, an apoptosis-
promoting member of the Bcl-2 family (Fulda, 2015).  
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Figure 2.4.2.: Apoptotic Pathway, Intrinsic and Extrinsic Pathways regulating Apoptosis  
Induction of apoptosis can be initiated through the intrinsic or extrinsic pathways 
(Jain, 2014)  
 
IAP (Inhibitor of Apoptosis) is another important family of the intracellular regulators, IAP were 
discovered originally as proteins produced by insect viruses; the viruses use them to prevent the 
infected cell from going into apoptosis and therefore give the virus enough time to replicate. They 
function to inhibit apoptosis in two ways: either by preventing the activation of by binding to some 
caspases or by binding to caspases to inhibit their activity (Fulda, 2015).  
.  
The mitochondria releases cytochrome c which will activate Apaf-1, it also releases a protein which 
will block IAPs; this will increase the efficiency of the process of death activation. Intracellular cell 
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death program can also be regulated by extracellular signals can inhibit or activate apoptosis, these 
extracellular signals act by regulating the activity or level of Bcl-2 and IAP family members (Labi, 
2015).  
 
2.5. Pyridine  
2.5.1. Chemical Properties 
Pyridine “azabenzene” an aromatic compound with the chemical formula C5H5N is a heterocyclic 
organic compound –figure 2.5.1., related to the benzene by replacing one methane group (=CH-) with 
more electronegative nitrogen, this will allow denoting a shift of electron density from the ring 
towards the nitrogen atom (Dorigo et al., 1993). 
 
 
 
Figure 2.5.1: Pyridine Ring. 
Pyridine Derivatives have the chemical formula C5H5N 
(Dorigo et al., 1993). 
 
 
Pyridine ring found in several compounds such as Azines (six-membered heterocyclic compounds 
group contains one or more nitrogen atoms in the ring and vitamin niacin, pyridoxal (vitamin B6) and 
in highly toxic alkaloids such as nicotine shows the evidence of the potent activity of the Pyridine 
(Abdel-Aziz et al., 2005). 
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In 1849 the Scottish chemist Thomas Anderson discovered Pyridine as a constituent of bone oil and 
coal tar, two years later he was able to isolate pure pyridine by the fractional distillat ion of the oil (Li 
et al., 1999). Korner and Dewar recognized that the cyclic nature of Pyridine in 1869 plays an essential 
role in catalyzing both their chemical and biological systems. Pyridine is the prosthetic nucleotide 
(NADP) which is involved in different oxidation-reduction processes (Abdel-Aziz et al., 2005) 
 
2.5.2. Pyridine Derivatives 
Pyridine derivatives obtain by acylation, alkylation, oxidation and nucleophilic substitution. Acyl 
chlorides or acid anhydrides react with pyridine to form N-acylpyridinium salts can be used as 
valuable transcyclating agents in alcohol. Pyridine used as a reagent and solvent. Pyridine also reacts 
with alkylating agents to form N-alkylpyridinium salts which can be isolated as crystalline solids, 
these compounds are much stable than their equivalents N-acylpyridinium (Srivastava et al., 2007). 
 
Researchers frequently use Pyridine N-oxides to facilitate the electrophilic substitution ; this type of 
reaction has a balance between electron withdrawal and release in the oxygen atom in the opposite 
direction. Pyridine also reacts with nucleophiles and the attack usually occurs at C-2(6) and/or C-4 by 
inductive effect, another classic reaction for Pyridine is Chichibabian amination which will lead to 2-
aminopyridine (Kim et al., 2010). Several substitutes attached to the pyridine ring have the similar 
chemical behavior of the corresponding groups in benzene, the most commonly encountered Pyridine 
derivatives are: Methylpyridines (Picolines), Pyridones (Hydroxypyridines), Aminopyridines and 
Pyridine salts (Abadi et al., 2009).  
 
Pyridine ring system and its derivatives have been found to be an important and versatile nucleus in 
the pharmaceutical field and considered as the panacea and solution for the control and management of 
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various diseases, it forms more than 7000 existing drugs in this industry. Recent research have found 
that pyridine and its derivatives have large and wide biological activities which include anticancer, 
antiviral, ant diabetic and antimicrobial etc (Allen et al., 2006). 4-(phenylamino) thieno[2,3-b]pyridine 
derivatives showed a potent inhibitory activity against Herpes Simplex Type I, while 4-(phenylamino)-
1H-pyrazolo [3,4-b] pyridine has shown different biological activities against HIV and Vaccı´nia 
virus. A well known pharmaceutical company synthesized 1-(β-D-ribofuranosyl)-pyridine-2-thiones to 
treat HIV infectious diseases, while another company synthesized imidazo [1,2-a]pyrrolo [2,3-c] 
pyridine series as an active agent against the swine fever virus (Bernardino et al., 2012).  
 
Pyridine derivatives have also shown antichagasic activity against Chagas’ disease, a parasitic 
infection caused by Trypanosoma cruzi, this parasite is widely spread in central, and South America. It 
is estimated about 20 million people are chronically infected with T. cruzi and about 100 million are at 
risk (Dorigo et al., 1993).   Dorigo (1993) synthesized a pyridine derivative, which has anti chagasic 
activity.  
 
Researchers have also discovered antioxidant activity such as Thiazolo [3,2-a] pyridine derivatives 
which was synthesized by Feng shi et al., this derivative scavenges free radicals. In addition pyridine 
derivatives has an antiviral and antifungal activity, Ivachtchenko synthesized 2-imino-5-
hydroxymethyl-8-methyl-2H-pyrano[2,3-c] pyridine-3-(N-aryl) carboxamides which is a novel drug 
has an anti-viral and anti-fungal activities (Dorigo et al., 1993).    
 
Pyridine derivatives show anti-cancer activity as shown in figure 1.4, Epothilones with a nitrogen 
atom at ortho position and methyl substitution on pyridine ring exhibited a cytotoxic properties against 
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several types of human cancel cell lines. 2,6-diaryl substituted pyridine showed cytotoxic and 
topisomerase I inhibitory activity against different human cancer cell lines (Wang, 2005).    
 
Heyakawa has synthesized a series of pyridine derivative called (imidazo[1,2-a]pyridine derivatives), 
thiazole derivative showed potent inhibition against p110a and strong selectivity for p110a over PI3K 
isoforms. It has also inhibited tumor growth by inhibiting PI3Kp110a which is now considered as a 
potential target in anti-cancer treatment (Cocco et al., 2005).  
  
2-amino-3-(3’,4’,5’-trimethoxybenzoyl)- 6-substituted-4,5,6,7-tetrahydrothieno [2,3-c]pyridine 
derivatives was synthesized by Romagnoli. This compound showed potential and promising anti-
tumor and anti-proliferative activity by affecting the cell cycle and inhibiting tubulin polymerization 
(Cocco et al., 2005).  
 
This derivative was tested against a panel of four different cell lines, which interacts strongly with 
colchicines site and tubulin. Furthermore, a novel oral indoline sulfonamide was synthesized by Lowe 
et al based on the disruption of the microtubules and thus exhibit a potent activity against cancer in 
human both in vitro and in vivo (Lowe, 1993).  
 
Recently Pyridine and its different derivatives showed strong cytotoxicity against several human 
cancer cell lines (Attia, 2003).  Some Pyridine derivatives such as Pyrazolo[4,3-d]pyrimidine analogue 
and pyrazolo[1,5-a] pyrimidine showed potent inhibition of tyrosine kinase and (CDK) cycline-
dependent kinases which are known to be involved in cellular events and transmission of mitogenic 
signals in the cell which will lead to uncontrolled proliferation, differentiation, immune response and 
metabolism. This pyridine derivative is responsible for blocking proliferation of different type of 
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cancer cell lines (Ruebsam et al., 2009). A novel study showed that 8-methyl-2-(morpholine-4yl)-7-
(pyridine-3-methoxy)-4H-1,3-benzoxacine-4-one (LTU27) has the ability to sensitize cancerous cells 
specifically lung cancer and colon cancer to radiation effect, treating the cells with both radiation and 
LTU27 increased the apoptosis and inhibited the auto-phosphorylation of DNA-PK and AKT1, 
LTU27 acts by inhibiting DNA-PK promoting apoptosis by delaying DNA repair (Radhamani et al., 
2014). 
 
Another Pyridine derivative with potent anti-proliferating effect is 4-thiazolidinone-, pyridine 
and piperazine-based conjugates. This compound exhibited good activity against human 
leukemic cell lines. The mechanism by which this compound worked is by inducing cell cycle 
arrest and depolarization of the potential of the mitochondrial membrane (Hazra et al., 2013).   
 
2.5.3. Cyanopyridine 
In the last few years, particular interest has been focused on cyanopyridine due to its diverse 
pharmaceutical activity (Lin et al., 2005), it has also been employed in the industrial production of 
nicotinic acid, nicotinamide and in several organic synthesis (Hazra et al., 2013). Cyanopyridine can 
fuse to different functional groups to form compounds with broad spectrum of pharmacological 
activity (Hazra et al., 2013) 
 
One of the most potent cyanopyridine derivatives is 2-oxo-3cyanopyridine a nucleus analogous to 
alkaloid Ricinine considered as the first alkaloid with cyano group. This compound has captured the 
researcher’s attention after the synthesis and study of the Milrinone a non-Glycosidiccardiotonic agent 
is an inhibitor of Dipyridinephosphodiesterase (Hazra et al., 2013). 
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Another important cyanopyridine derivative is 3-cyano-2 Pyridone. This derivative has shown 
promising and potent anti-cancer activity which is known to be due to its interference with PDE3, 
P1M1, Kinase and Survivin proteins. The 3-cyanopyridines compounds with different alkyl or 
aryl/heteroaryl groups were found to possess anti-tubercular, antimicrobial, anti-cancer, 
antihypertensive, anti- inflammatory as well as antiviral activity against herpes virus and human 
immunodeficiency virus (Radhamani et al., 2014). 
 
Careful literature survey revealed that incorporation of alkoxy substituents (methoxy and/or aryloxy 
moieties) results in significant enhancement of several biological activities due to magnification of 
compounds' lipophilicity (Radhamani et al., 2014). In addition to 3-cyano-2(1H)-pyridone, pyridine-2-
thione and pyrazolopyrimidine derivatives received considerable attention due to their activity as anti-
cancer, anti-inflammatory, anti-mycobacterial, anti-fungal and anti -viral drugs (Radhamani et al., 
2014). 
 
2.6. Pyridine Derivatives and Apoptosis 
Apoptosis is not associated with the activation of the immune response; considered a desirable feature 
in anti-cancer drugs. The intrinsic apoptotic pathway or the mitochondrial pathway activated upon 
cellular stress signals resulting from DNA damage, loss of cell survival factors and cell cycle failure 
(Sharath Kumar et al., 2014).  
 
Research has found that micronuclei can be induced following the exposure to clastogenic or 
aneugenic agents and can be used as a sensitive tool in assessing genotoxicity; studies have shown that 
micronucleated cells can be eliminated by the apoptotic process involving caspase 9, 8 and 3. A study 
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entitled (synthesis and biological evaluation of novel 3-alkylpyridine marine alkaloid analogs with 
promising anti-cancer activity) in 2014 has shown that novel 3-APA -3 alkylpyridine alkaloid have a 
promising anti-cancer activity by inducing apoptosis in tumor cell lines and altering the cellular actin 
cytoskeleton of colon cancer cell lines (Deslandes et al., 2012). Phosphodiesterases such as PDE3, 
PDE4 and PDE5 are over-expressed in cancerous cells when compared to normal cells, therefore 
inhibiting phosphodiesterases will lead to the inhibition of tumor proliferation and angiogenesis 
(Deslandes et al., 2012).  
 
It has been found that inhibition of PDE3 inhibited the uncontrolled growth of HeLa squamous cell 
carcinoma cell line and HSG cell lines. Cilostamide, which is another pyridine derivative has a 
selective PDE3 inhibitor was found to have synergism action to anti apoptotic activity of PDE4 
inhibitors in leukemic cells. It has been reported that PDE5 inhibitors would increase the sensitivity of 
certain cancer types to the convention chemotherapeutic drugs (Abadi et al., 2009).   
 
2-oxo-3-cyanopyridine derivative, 4,6-diaryl-2-oxo-1,2-dihydropyridine-3-carbonitriles has shown 
significant inhibition to PIM-1  (Proto-oncogenic encodes for serine/ threonine kinase) which is over 
expressed in variety of cancers cells (Lin et al., 2005). Furthermore, 2-oxo-3-cyanopyridine can inhibit 
Survivin which is a protein encoded by BIRC5 gene and which is known to be over expressed in some 
cancers, Survivin is also a member of IAP, increase levels of Survinin in tumor cells is associated with 
poor prognosis and low survival rates (Gundugola et al., 2010). 
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3. Materials: 
3.1. Pyridine Derivatives: 
Compound No. Structure Molecular Weight R Group 
4a 
 
406.43 CH3 
4b 
 
420.46 C2H5 
4d 
 
448.47 CH2COCH3 
5 
 
478.49 - 
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Compound No. Structure Molecular Weight R Group 
6 
 
464.47 - 
7a 
 
554.64 CH3 
7b 
 
568.66 C2H5 
7c 
 
653.77 Morpholinoethyl 
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Compound No. Structure Molecular 
Weight 
R Group 
7d 
 
651.8 - 
8a 
 
582.6 4-OCH3C6H4 
8b 
 
612.63 3,4-OCH3C6H3 
8c 
 
642.66 3,4,5-OCH3C6H2 
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Compound No. Structure Molecular 
Weight 
R Group 
9a 
 
568.6 C6H5 
9b 
 
568.58 4-OCH3C6H4 
10 
 
604.63 - 
11 
 
528.5558 - 
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Compound 
No. 
Structure Molecular 
Weight 
R Group 
12 
 
530.5286 - 
13 
 
586.6183 - 
15 
 
619.645 - 
17 
 
506.5304 - 
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3.2. Cell Lines 
No Cell Lines ATCC 
1 MCF-7 HTB-22 
2 MDA-MB-231 HTB-26 
3 HCT-116 CCL-247 
4 SK-OV-3 HTB-77 
5 OVCAR-3 HTB-161 
6 MCF-12A CRL-10782 
 
 
3.3. Chemicals used for cell culture 
No Reagent Company 
1 DMSO SIGMA 
2 Ethanol 95% - 
3 Feto Bovine Serum (FBS) - 
4 Dulbecco’s Phosphate Bufferred Saline (PBS) SIGMA-ALDRICH, Co. 
5 Dulbecco’s Modified Eagle’s Medium (DMEM) SIGMA-ALDRICH, Co. 
6 RPMI medium (1640) 1X Gibco – Life Technologies 
7 Penicillin/Streptomycin 1% ThermoFisher Scientific  
8 Trypsin 1x - 
9 WST-1 Roche Diagnostics GmbH 
 
 
3.4. Chemicals used for Cell Proliferation Assay 
No Reagent Company 
1 WST-1 Roche Diagnostics GmbH 
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3.5. Chemicals used for Flow Cytometry Analysis 
No Reagent Company 
1 RNase SIGMA-ALDRICH, Co. 
2 PI “Propidium Iodide” SIGMA-ALDRICH, Co. 
3 Annexin V-FITC Apoptosis Detection Kit SIGMA-ALDRICH, Co. 
 
 
3.6. Chemicals used for Western Blot 
No Reagent Company 
1 P53 Monoclonal Antibody ABCAM 
2 Bcl-2 Monoclonal Antibody ABCAM 
3 PBS SIGMA-ALDRICH, Co. 
4 P21 monoclonal Antibody ABCAM 
5 Bax Monoclonal Antibody ABCAM 
6 Mdm-2 Monoclonal Antibody ABCAM 
7 Akt Monoclonal Antibody ABCAM 
8 Pro-Caspase-3 Monoclonal Antibody ABCAM 
9 Caspase-3 Monoclonal Antibody ABCAM 
10 30% Acrylamide Mix Sigma 
11 1.5M Tris (pH 8.8) - 
12 10% SDS Life Technologies 
13 10% APS Life Technologies 
14 TEMED Sigma 
15 10% Protease Inhibitor Sigma 
16 PMSF (100mM) Sigma 
17 RIPA Lysing Buffer Sigma 
18 Chemiluminescence Reagent Life Technologies 
19 Secondary Anti-Rabbit Ig  Sigma 
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4. Methods:  
4.1. Cell Line and Cell Culture: 
Studying different cell lines is important in determining if the effect of pyridine derivatives is cell or 
tumor-type specific, tumor type specific. The following cell lines were used for the screening stage, 
obtained from the American Type Culture Collection (ATCC, Menassas, Virginia, USA): 
 
 MDA-MB-231 (ATCC HTB-26) is an adherent epithelial mammary/gland breast cells derived 
from metastatic sites of pleural effusion from a 51 years female adult with adenocarcinoma. 
 MCF-7 (ATCC HTB-22), adherent epithelial cells of the mammary gland/breast from 
metastatic site of pleural effusion but derived from 69 years old Caucasian female adult. 
 HCT-116 (CCL-247) is adherent epithelial cells derived from an adult male with colorectal 
carcinoma; this cell line has a mutation in RAS proto-oncogene in codon 13.  
 SK-OV-3 (HTB-77) is adherent ovarian epithelial cells derived from 64 years old Caucasian 
female with adenocarcinoma  
 OVCAR-3 (HTB-161) is adherent ovarian epithelial cells derived from 60 years old Caucasian 
female respectively with adenocarcinoma and is a suitable ovarian cell model to study drug 
resistance in ovarian cancer.  
 MCF-12A (ATCC CRL-10782) is adherent epithelial mammary cells derived from 60 years 
old Caucasian female.  
 
Sub-culturing of the above cell lines was conducted in 75cm2 flasks, the old culture media was 
removed and discarded after assessing the confluency of the cells, the cells were rinsed with 2-3 ml 
diluted Trypsin 1x (Trypsin/EDTA solution consist of 0.025% trypsin and 0.01% EDTA in (PBS),) for 
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about 5 minutes for complete detachment. The cells were observed under the inverted microscope until 
the cell layer is completely dispersed. 75cm2 flasks were prepared and 16 ml of DMEM media for 
MCF-7, MDA-MB-231, T-47D, SK-OV-3 and OVCAR-3 (DMEM 4500mg Glucose) and RPMI 
media for HCT-116 were added to each flask, the cells were aspirated gently and added to the flasks. 
DMEM 4500 mg/L high glucose with 10% FBS and 5% Streptomycin and Penicillin, RPMI 1640 was 
prepared by adding 5% heat-inactivated FCS and 2 mM glutamine. DMEM was also used for MCF-
12A cells with the addition of human epidermal growth factor 20ng/ml, insulin 0.01 mg/ml and 
hydrocortisone 500ng/ml.  
 
The cells were incubated for 3 days before propagation to treatment at 37°C with 5% CO2 and 95% air 
for stabilization. The medium was renewed 2-3 times a week. Further sub-culturing were carried out at 
a ratio of 1:3 to 1:6 according to the confluency of the cells. Usually it was done when cells reached 
75-85% confluence after 3 days. For splitting the medium was aspirated and cells were incubated for 5 
minutes with trypsin, cells were then cultured in the desired dilution into new flasks, growing cells 
were used for all experiments. 
 
Cell Line Culture 
 
Image 
a. MCF-7 
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b. MDA-MB-231 
 
c. HCT-116 
 
d. OVCAR-3 
 
 
e. SK-OV-3 
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f. F. MCF-12A 
 
 
Figure 4.1. Selected Cancer Cell Lines Screened in the Study. a. MCF-7, b. MDA-MB-231, c. HCT-116, d. OVCAR-3 & 
e. SK-OV-3 
 
4.2. Cell Count using Hemacytometer: 
Hemocytometer is a counting chamber device used to perform cell count by measuring the 
concentration of cells in a suspension. The central area of the instrument is defined by a set of grooves 
that form “H” shape, two counting areas with ruled grids are separated by a horizontal groove of the 
“H” each counting area consist of 9 squares (1.0 mm X 1.0 mm) covered by a glass cover-slip at 
0.1mm above the surface of the counting area. Cell count is down by adding 10 µL of cell suspension 
to the counting chamber in each slide; in WST-1 Assay a cell count of about 50,000 cells/mL was 
achieved.  
 
4.3. Drug Stock Preparation: 
- Twenty Pyridine Derivatives compounds numbered {4a – 4b – 4c – 4d – 5 – 6 – 7a – 7b- 7d- 
8a – 8b – 8c – 9a – 9b – 10 – 11- 12- 13 -15 - 17} were provided to investigate their role as 
novel anti-cancer compounds. 
- Compounds as illustrated in the material section were prepared for further assays. 
- The next step was optimization of the compounds, pyridine derivatives are organic highly 
hydrophobic compounds, and therefore DMSO was used as the best organic solvent. A 
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concentration of 0.4% DMSO was used in all experiment after ensuring 100% viability of the 
cell lines with this concentration. 25mM stock concentration of all compounds were prepared 
for further studies and analysis. 
- TPEN (N,N,N′,N′-Tetrakis(2-pyridylmethyl)ethylenediamine) was used as positive control in 
tests. TPEN is a lipid soluble compound with high affinity to heavy metal including (Zn2+-
Fe2+-Mn2+), TPEN permeate plasma membranes and induce apoptosis through the activation of 
caspase-3 (Santa Cruz Biotechnology, 2015). 
 
 
Figure 4.2. TPEN (N,N,N′,N′-Tetrakis(2-pyridylmethyl)ethylenediamine) Structure 
http://www.scbt.com/datasheet-200131-tpen.html 
 
 
4.4. Cell Viability Assay (WST-1 Assay): 
WST-1 is a clear, slightly red and ready to use cell proliferation reagent, the reagent contains WST-1 
and electron reagent diluted in phosphate buffered saline and filtered for use. WST-1 assay has several 
applications including the analysis of cytotoxicity by anti-cancer drugs and other types of 
pharmaceutical compounds. The assay principle is based on cleaving Tetrazolium salts to Formazan 
by the cellular enzymes of viable cells; an increased number of viable cells indicates an increased 
activity of mitochondrial dehydrogenases. Therefore, the increase in Formazan dye formation can 
directly be linked to the number of metabolically viable active cells in the culture. WST-1 has recently 
show better results and is easier to conduct than MTT Assay in which the MTT reagent will be cleaved 
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to water insoluble Formazan crystals and therefore requires solubilization after cleavage, while WST-1 
yields water-soluble products can be measured directly without the need for extra solubilization step. 
 
WST-1 was carried out as follows: the cells were trypsinized and put in 15ml falcon tube, the cells 
were centrifuged for 3 min at 1000rpm. 1x Trypsin is decanted using a sterile pipette and then the 
pellet is loosened by flicking the tube few times, 5-10 mL warm DMEM or RPMI were added to the 
falcon tube and the pellet is re-suspended. Cell count was done next by taking 10uL of the suspension 
into the cell counting slide and read under 10X cells/ml. A cell stock of 50,000 cells/ml was prepared 
for the 96 wells. 100uL of cells added to each well using a sterile pipette each time to ensure 
consistency. The experiment was planned ahead of time using excel sheet, 3-6 wells were reserved as 
media blank while 3-6 wells for vehicle (DMSO). The plate incubated for 24 hours for drug treatment 
step.  
 
DMEM media was used to prepare different dilutions of the compounds. The old DMEM media was 
removed from the wells using sterile pipette in the hood, the media was replaced with 100 uL media 
with each compound. The plate was incubated for 24 hours. After 24 hours incubation WST-1 reagent 
was added to each well and then the plate was incubated for 1 hour before reading using 
spectrophotometer (VICTOR Multilabel Plate Reader).  
 
The absorbance of this colored solution can be quantified by measuring at a certain wavelength 
(usually between 500 – 600 nm), in this experiment the first reading was conducted at 540 nm and the 
second reading at 690 nm for the reference wavelength. 
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4.5. Morphological Examination: 
Morphological examination was performed as described previously; DMA-MB-231, MCF-7, HCT-
116, SK-OV3 and OVCAR-3 cells were plated on 96 well plates at 5*104 cells/well; and allowed to 
reach 75-85% confluence. The compounds were added to the medium, untreated cells were used as 
negative control, in addition to blank cells (medium) and vehicle which consist of (DMSO 0.4% + 
cells), TPEN was used as a positive control. After the treatment all the cells were incubated for 24 
hours in atmosphere containing 5% CO2 for 24h. After 2 hours of treatment, the morphological 
changes of the cells were examined and photographs were taken using an inverted microscope at 400X 
magnification microscopy.  
 
4.6. Dose Response Curve: 
The Dose Response Curve relationship is essential to describe the change in the cell lines by different 
levels of doses after a certain time exposure; it is often referred to as a “graded” response because the 
measured effect is continuous over a range of doses. Studying and developing the dose response curve 
is essential to determine the safe and hazardous levels of the drug, in addition it identifies the acute 
toxic effect of the drug and potential pollutants. Several guidelines and reports on dose response 
modeling were developed by U.S. Environmental Protection Agency. Dose response curve was 
performed on compound 9a on MCF-7 cell lines as follows, several doses of compound 9a were 
prepared; 0.5 µM, 1 µM, 5 µM, 20 µM, 50 µM & 100 µM. MCF-7 cell line passage 30 were seeded in 
75cm2 flask, after being confluent the cells were trypsinized and kept in 15 ml falcon tube, centrifuged 
for 3 min at 1000rpm. The supernatant was decanted by glass pipette and the pellet was re-suspended 
in 8 ml DMEM. Cell count was carried out using the cell counter, a cell stock of 50,000 cells/ml was 
prepared and 100ul of the cells were seeded in 96 wells plate as planned. 
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The dose response curve was planned ahead using Excel sheet to include a triplet of each of the 
following doses 0.5µM, 1µM, 5µM, 20µM, 50µM and 100µM. TPEN was also used as a control at the 
same range of doses. The cells were treated with the planned doses and incubated for 24h incubation, 
WST-1 reagent was used and the plate was read by VICTOR Multilabel Plate Reader at two 
wavelengths as explained earlier. Negative and vehicle controls were also added to the experiment.  
 
4.7. Flow Cytometry: 
3.7.1. Cell Cycle Analysis 
This assay depends on assessing plasma membrane integrity of the treated cells using (PI). PI is taken 
by cells, which loose its plasma membrane integrity, and thus allows the uptake of the PI dye; this 
essay does not distinguish between apoptosis or necrosis but only distinguish between dead and alive 
cells. However, apoptosis cause the shrinkage of the cells but not necrosis, so a combination of 
reduced FSC and the uptake of PI can be used to decide the mode of cell death. MCF-7 cells were 
seeded in 25cm2 flask until reaching the desirable confluence of 1 million cells; media was changed to 
media containing compound 9a (20µM), after 24hours incubation the cells were harvested by 
Trypsinization to detach the cells without affecting the integrity of the cell membrane.  
 
The cells have been incubated with PI for 5 min at room temperature, wash twice with PBS and fixed 
with ice-cold 70% Ethanol while vortexing. Then the cells were washed and re-suspended in PBS with 
5 g/ml RNase A and 50 g/ml PI for analysis by flow cytometry. Cell cycle analysis by using FACScan 
Flow Cytometer and as per the manufacturer protocol.  
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4.7.2. Apoptotic Assay 
This assay is rapid and sensitive protocol to detect early and late apoptosis, and to differentiate if the 
treated cells have gone apoptosis or necrosis process. When the cells go under apoptosis, they 
translocate phophatidylserine (PS) from the inner plasma membrane to the outer plasma membrane 
“the cell surface”. This will allow the detection of apoptotic cells when the fluorescent conjugate 
Annexin V (FITC) binds to PS on the cell surface. 
 
Annexin-V is a protein with high affinity to phosphatidyleserine. This assay can be performed on live 
cells and the procedure takes about 10 min to accomplish without fixation. The procedure also 
contains PI to distinguish between viable cells (FITC negative/ PI negative), early (FITC positive/PI 
negative) or necrosis/late apoptosis (FITC positive/PI positive. FITC is excited by the blue laser at 488 
nm while PI by the green laser at 552 nm.  
 
The procedure was performed as following: MCF-7 cells were cultured in 75cm2 flask until reaching 
75-85% confluence, the cells were then trypsinized with 1x Trypsin. The cells were centrifuged to 
discard the trypsin and the pellet was re-suspended in 5ml DMEM media. Cell count was performed 
and 2.5X105 cells were then cultured in 6 well plate for further treatment. The test was done in 
triplicate for compound 9a, unstained cells were used as a negative control, cells with DMSO 0.4% 
was also tested and cells treated with TPEN was used as a positive control. When MCF-7 cells were 
confluent, treatment was carried out with compound 9a at 20µM in triplicate. The cell were incubated 
for 24 hours to be propagated for flow cytometry apoptosis detection. The media in the 6 well plate 
was aspirated to 15ml conical tube and placed on ice immediately as this media contain a number of 
detached cells during the death process.  
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The adherent cells were then washed out using PBS, the PBS was removed to be trypsinized then with 
0.5x trypsin and released firmly. The cells were re-suspended in 1x cold binding buffer to 1 x 106 
cells/ml and 0.5 ml of the suspension to microfuge tubes, 10µl of the media binding reagent and 1.25ul 
of Annexin V-FITC were added to the tubes, the tubes were incubated for 15 minutes at RT in the 
dark. The tubes were then centrifuged for 5 minutes and the media was removed.  
The pellet was then resuspended in 0.5ml of cold 1x binding buffer, followed by adding 10µl PI, the 
tubes were placed in ice in dark before flow cytometry analysis. Flow Cytometry analysis was 
performed at 488 nm using the blue laser and 552 nm using the green laser.  
 
4.8. Western Blot: 
Western blot analysis is used to detect specific proteins in a sample. The proteins are separated by gel 
electrophoresis and then transferred electrophoretically to a PVDF membrane. Antibodies are used to 
detect the specific proteins that are immobilized on the membranes. Prior to blotting an SDS-PAGE 
gel was stained with coomassie blue to provide visual confirmation that equivalent amounts of various 
samples were being analyzed. For analysis of Bcl-2, p53, caspase-3, p21, mdm-2 and Akt proteins, 
MCF-7 cells were collected and lysed in RIPA lysis buffer after 24 hours of treatment. Membranes 
were re-probed with β-actin protein antibody to confirm equal loading of protein samples. Protein 
Expressions was tested by using monoclonal antibodies and measuring the total cellular protein by 
western blot. The sample and the loading dye were normalized, then the sample was heated to 95ₒC for 
about 5 min and then the protein was separated on SDS-PAGE. After that, the protein was incubated 
with primary antibodies overnight at a 1:500 dilution in 5% PBS, a three-time wash was carried out 
before the incubation with the secondary antibodies.  
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5. Results: 
 
5.1. Cell Viability:  
Measurement of cell viability and proliferation forms the basis for numerous in vitro assays of a cell 
population’s response to external factors. The reduction of tetrazolium salts is now widely accepted as 
a reliable way to examine cell proliferation. WST Assay was performed to evaluate the effect of 20 
Pyridine Derivatives 4a – 4b – 4d – 5 – 6- 7a – 7b – 7c – 7d - 8a – 8b – 8c - 9a – 9b – 10 – 11 – 12 – 
13 – 15 and 17 on MCF-7, MD-MB-231, HCT-116, SK-OV-3 and OVCAR-3. The cell lines were first 
treated first with 100 µM of the compounds for 24 hours. Samples were normalized to untreated 
control.  
 
 
 
 
Figure 5.1.1 Cell Viability Assay for MCF-7 cells. The percentage of viability after treatment with 100 µM (4a-4b-4d-5-6-
7a-7b-7c-7d-8a-8b-8c-9a-9b-10-11-12-13-15-17 for 24h) using WST-1 Assay. Each graph is an average of results from 
one experiment performed in triplicate and presented as M ± SD. Cells without Pyridine Derivatives treatment were used 
as control, TPEN 100 µM was used as a positive control using WST-1 Assay.   
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Figure 5.1.2. Cell Viability Assay for MDA-MB-231 cells. The percentage of viability after treatment with 100 µM (4a-
4b-4d-5-6-7a-7b-7c-7d-8a-8b-8c-9a-9b-10-11-12-13-15-17 for 24h) using WST-1 Assay. Each graph is an average of 
results from one experiment performed in triplicate and presented as M ± SD. Cells without Pyridine Derivatives treatment 
were used as control, TPEN 100 µM was used as a positive control using WST-1 Assay.   
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Figure 5.1.3. Cell Viability Assay for HCT-116 cells. The percentage of viability after treatment with 100 µM (4a-4b-4d-
5-6-7a-7b-7c-7d-8a-8b-8c-9a-9b-10-11-12-13-15-17 for 24h) using WST-1 Assay. Each graph is an average of results from 
one experiment performed in triplicate and presented as M ± SD. Cells without Pyridine Derivatives treatment were used 
as control, TPEN 100 µM was used as a positive control using WST-1 Assay.   
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Figure 5.1.4. Cell Viability Assay for SKOV-3 cells. The percentage of viability after treatment with 100 µM (4a-4b-4d-5-
6-7a-7b-7c-7d-8a-8b-8c-9a-9b-10-11-12-13-15-17 for 24h) using WST-1 Assay. Each graph is an average of results from 
one experiment performed in triplicate and presented as M ± SD. Cells without Pyridine Derivatives treatment were used 
as control, TPEN 100 µM was used as a positive control using WST-1 Assay.   
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Figure 5.1.5. Cell Viability Assay for OVCAR-3 cells. The percentage of viability after treatment with 100 µM (4a-4b-4d-
5-6-7a-7b-7c-7d-8a-8b-8c-9a-9b-10-11-12-13-15-17 for 24h) using WST-1 Assay. Each graph is an average of results from 
one experiment performed in triplicate and presented as M ± SD. Cells without Pyridine Derivatives treatment were used 
as control, TPEN 100 µM was used as a positive control using WST-1 Assay.   
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5.2. Potent Pyridine Derivatives 
The potent derivatives that reduce cell viability by 50% were summarized for further investigations as 
shown in in table 5.1. 
 
Table 5.1 Potent Pyridine Derivatives 
 
 
 
 
 
 
 
 
 
 
 
5.3. Compound 9a and MCF-7 cells 
 
   
 
Figure .3.1. Compound 9a Structure with the chemical formula C30H28N4O7  
 
 
 
 
Compound Cell Line Viability % Concentration 
9a MCF-7 40% 100 µM 
9a HCT-116 45% 100 µM 
7b SKOV-3 35% 100 µM 
11 MCF-7 44% 100 µM 
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Compound 9a is a Pyridine Derivative, an organic aromatic compound miscible with organic solvents. 
Compound 9a is a weak base due to the presence of lone pairs of electrons at the nitrogen center. 
Pyridine is protonated when reacting with acids. Compound 9a is soluble in DMSO “dimethyl 
sulfoxide” an organosulfur colorless solvent.  
 
Figure 5.3.2. 3D Structure of Compound 9a  
 
 
5.4. Morphological Changes of MCF-7 cells after 24h treatment with different concentration 
of compound 9a 
The morphological changes in MCF-7 cells were followed up after the treatment with different 
concentrations of compound 9a (0.5, 1, 5, 20, 50 and 100 µM). At 0.5, 1 and 5 µM no morphological 
changes were observed, however upon treating the cells with higher concentrations of 20, 50 ad 
100µM apoptotic features were observed including marked apoptotic bodies and cell shrinkage in a 
concentration dependent manner. Untreated cells were used as a negative control. Treatment of MCF-7 
cells with DMSO 0.4% did not show any death of the cells.  
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Figure 5.4.1. Effect of 9a on morphological appearance of MCF-7 cells. The morphological appearance of MCF-7 cells 
after treatment with 0.5, 1, 5, 20, 50 and 100µM of compound 9a for 24h. MCF-7 IC50 (20µM) induces apoptotic 
programmed cell death including marked apoptotic bodies and cell shrinkage in a concentration dependent manner. 
Untreated cells were used as a negative control. Treatment of MCF-7 cells with DMSO 0.4% did not show any death of the 
cells.  
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The morphological changes were also observed in MCF-7 using TPEN as a positive control. TPEN 
IC50 of 5µM was capable of inducing apoptosis as shown hereunder. The apoptotic effect of TPEN 
increased dramatically with higher concentrations.  
 
 
                               
 
Figure 5.4.2. The morphological appearance of MCF-7 cells after treatment with 0.5, 1, 5, 20, 50 and 100µM of TPEN for 
24h. MCF-7 IC50 (20µM) induces apoptotic programmed cell death including marked apoptotic bodies and cell shrinkage 
in a concentration dependent manner. Untreated cells were used as a negative control. Treatment of MCF-7 cells with 
DMSO 0.4% did not show any death of the cells.  
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5.5. Dose Response Curve & IC50 
For further experiments, dose response curve was constructed, it is essential to describe the changes in 
cell viability using different doses after a certain time of exposure. The dose response curve is referred 
as the graded response because the measured effect is continuous over the range of different doses. 
Therefore, several doses of compound 9a were prepared ranging from; 0.5 µM, 1 µM, 5 µM, 20 µM, 
50 µM & 100 µM and the IC50 was calculated as 20 µM.   
 
 
 
 
Figure 5.5.1. Dose response curve of compound 9a in MCF-7 cells. Different concentrations of compound 9a were used 
ranging from 0.5µM to 100µM and blotted against the cell viability as a percentage.  
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The dose response curve was also constructed for the positive control TPEN (the positive control) as 
illustrated in figure 5.5.2. 
 
 
 
 
Figure 5.5.2. Dose response curve of TPEN in MCF-7 cells. Different concentrations of TPEN were used ranging from 
0.5µM to 100µM and blotted against the cell viability as a percentage.  
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5.6. Cytotoxicity of compound 9a on non-tumorigenic breast epithelial cells MCF-12a & 
Statistical Analysis 
In order to assess the level of cytotoxicity of compound 9a in non-tumorigenic breast epithelial cells, 
MCF-12a were treated with 20 µM for 24hours and WST-1 assay was carried out as described in 
section of materials and methods. The viability of MCF-12a cells were blotted on bar graph in 
comparison with MCF-7 after the same treatment. The significance of viability between MCF-7 and 
12a was calculated SPSS non-parametric analysis of two independent sample test as explained 
hereunder.  
 
 
 
Figure 5.6.1. Cytotoxicity of compound 9a on non-tumorigenic breast epithelial cells MCF-12a. WST-1 Assay was 
performed on MCF-7 and MCF-12a after treatment with compound 9a 20 µM for 24 hours. The viability in MCF-12a was 
about 75% in comparison with MCF-7 48%. Each data point was an average of results from three independent experiments 
performed in triplicate and presented as M ± SD.  
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Statistical Analysis to calculate the Statistical Significance of viability in MCF-7 and MCF-12A: 
 
Normality for MCF-7 and MCF-12A was tested using SPSS software by two methods: Kolmogorov-
Smirnov (K-S test) with specified mean and variance and Shapiro-Wilk with unspecified mean and 
variance. K-S test is a sensitive useful nonparametric test method used to compare the probability 
distribution of continuous samples, by measuring the empirical distribution function between two 
samples, in this case MCF-7 and MCF-12A based on the null hypothesis that MCF-7 and MCF-12A 
are drawn from same distribution (Zaiontz, 2014). Shapiro-Wilk is another widely used nonparametric 
test for normality, the significance in both methods was 0.004 as illustrated in table 5.3., as the 
obtained p value was < 0.05 then the null hypothesis should be rejected which indicates that the 
obtained data for MCF-7 and MCF-12A were deviated from normal distribution. Q-Q Plot was also 
performed to determine the normality graphically beside numerically, however the data points were 
not distributed closely to the diagonal line, did not present a linear fashion ("Testing for Normality 
using SPSS Statistics," 2014).  
 
Table 5.6.1. Testing Normality in MCF-7 and MCF-12a using SPSS  
 
Descriptive 
 Statistic Std. Error 
Treats Mean .7041 .04983 
95% Confidence Interval for 
Mean 
Lower Bound .6017  
Upper Bound .8065  
5% Trimmed Mean .7109  
Median .7200  
Variance .067  
Std. Deviation .25891  
Minimum .27  
Maximum 1.00  
Range .73  
Interquartile Range .53  
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Skewness -.204 .448 
Kurtosis -1.395 .872 
 
 
 
Table 5.6.2. Testing Normality in MCF-7 and MCF-12a using SPSS “Kolmogorov-Smirnov” and “Shapiro-Wilk” 
 
Tests of Normality 
 
 
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic Df Sig. 
Treats .207 27 .004 .876 27 .004 
 
 
  
 
 
Figure 5.6.2 Q-Q plot for MCF-7 and MCF-12A  
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Since the viability does not satisfy the normality assumption and due to small sample size, the Non-
parametric approach has been used to assess the viability significance between MCF-7 and MCF-12a 
after treatment with 20µM of compound 9a for 24 hours:  
 Kruskal-Wallis Test was used to compare the three independent groups (control – MCF-7 and 
MCF-12A), kruskal-Wallis is a nonparametric method for testing more than two samples to 
evaluate whether they originate from the same distribution. It is an equivalent test to the 
parametric test ANOVA for the one-way analysis of variance (McDonald, 2014). The results of 
this test has shown statistical significance of p value 0.001 as indicated in table 5.4.  
 
 
Table 5.4 Statistical Significance for three groups (MCF-7, MCF-12a and control) using Kruskal Wallis method 
 
Ranks 
 
Groups N Mean Rank 
Treats 1.00 9 5.00 
2.00 9 14.00 
3.00 9 23.00 
Total 27  
Test Statisticsa,b 
 Treats 
Chi-Square 24.076 
Df 2 
Asymp. Sig. .001 
a. Kruskal Wallis Test 
b. Grouping Variable: groups 
 
 
 Mann-Whitney was also carried out to compare both groups (treated MCF-7 cells and MCF-
12A). Mann-Whitney is a nonparametric test for comparing two independent groups, based on 
the null hypothesis which indicates that both groups come from the same population. This test 
has shown higher efficacy than t-test on data with non-normal distribution ("Mann-Whitney U 
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Test using SPSS," 2014). Rejecting the null hypothesis indicates that viability in MCF-7 and 
MCF-12A is different. The results showed statistical significance of p value 0.001.  
 
 
Table 5.5 Statistical Significance for two groups (MCF-7, MCF-12a) using Mann-Whitney U method 
 
  Ranks 
 
Groups N Mean Rank Sum of Ranks 
Treats 1.00 9 5.00 45.00 
2.00 9 14.00 126.00 
Total 18   
Test Statisticsa 
 Treats 
Mann-Whitney U .000 
Wilcoxon W 45.000 
Z -3.589 
Asymp. Sig. (2-tailed) .001 
Exact Sig. [2*(1-tailed Sig.)] .001b 
a. Grouping Variable: Groups 
b. Not corrected for ties. 
 
Using both non-parametric statistical analysis methods: Mann-Whitney U and Kruskal-Wallis Test, 
the results show statistical significance of p value 0.001 in viability between MCF-7 and MCF-12a 
after treatment with 20µM of compound 9a. 
 
5.7. Apoptosis Detection Assay Annexin-V FITC 
This assay was used to detect apoptosis in MCF-7 cells after treatment with IC50 (20 µM) compound 
9a for 24hours, the results showed that about 51.7% of the total population were viable cells, 48.3% 
represents cells in early apoptosis, late apoptosis and dead cells. The apoptosis detection assay was 
also performed for the positive control TPEN.  
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Figure 5.7.1. Compound 9a induces apoptosis in MCF-7. Viable cells constitute 51.7% of the total population, cells in 
early apoptosis were 1.3%, cells in late apoptosis are 42.4% and dead cells are 3.1%. The data represented is an average of 
three independent experiments performed in triplicate. MCF-7 cells were treated by compound 9a for 24h before analysis.  
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Figure 5.7.2. TPEN induces apoptosis in MCF-7. Viable cells constitute 34.7% of the total population, cells in early 
apoptosis were 5.9%, cells in late apoptosis are 25.4% and dead cells are 34%. MCF-7 cells were treated by TPEN for 24h 
before analysis “as a positive control”.  
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Figure 5.7.3. 3D Orientation Structure of Apoptotic Detection Assay by Flow Cytometry presenting the different 
populations of viable cells, MCF-7 cells in early apoptosis, MCF-7 cells in late apoptosis and dead MCF-7 cells . a. 3D 
structure of unstained MCF-7 cells. b. 3D structure of untreated MCF-7 with the vehicle DMSO 0.4%. c. 3D structure of 
MCF-7 cells treated with TPEN “+ve control”. d. 3D structure of MCF-7 cells treated with compound 9a IC50 “20µM”for 
24hours.  
 
 
 
Figure 5.7.4. Histogram representing the Late Apoptotic Phase by Flow Cytometry. a. Histogram of untreated MCF-7 
cells. b. Histogram of MCF-7 cells treated with compound 9a for 24hours. c. Histogram of MCF-7 cells treated with TPEN 
for 24hours.  
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5.8. Cell Cycle Analysis 
The analysis of the cell cycle checkpoints revealed no significant differences between the untreated 
and treated MCF-7 cells as illustrated in figures 5.8.1 and 5.8.2. A slight reduction of about 5% in 
G2/M phase was observed in MCF-7 cells treated with compound 9a (20 µM).  
 
           
 
 
 
Figure 5.8.1. Cell Cycle Analysis of total 10,000 events of untreated MCF-7 cells. 37.2% of the total cell population was 
in G0/G1 phase, 25.7% in Phase S and 17.9 in G2/M phase.  
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Figure 5.8.2. Cell Cycle Analysis of total 10,000 events of MCF-7 cells treated with 20 µM of compound 9a for 24 hours. 
45.3% of the total cell population was in G0/G1 phase, 27.1% in Phase S and 13.7 in G2/M phase.  
 
 
 
5.9. Impact of 9a on Apoptotic and Survival Signals 
Several key downstream components are involved in the regulation of cell cycle. p53, “the Guardian 
of The Genome”, is an important protein in cell cycle and apoptosis, loss of its function will result in 
cancer. p53 trans-activates other tumor suppressor down-stream genes involved in cell cycle arrest and 
apoptosis such as p21 and Bax. To elucidate the role of p53, p21 and Bax in the anti-tumor activity of 
compound 9a, MCF-7 cells were treated with IC50 (20 µM) of compound 9a for 24 hours compared 
with untreated cells serving as a control. The lysates of both treated and untreated cells were prepared 
and processed for western blot analysis to study the changes in the levels of p53, p21 and Bax in order 
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to evaluate the effects of compound 9a on these pathways. In this study, compound 9a increased the 
expression of p53, p21 and Bax in MCF-7 in treated cells compared to untreated cells.  
 
 
 
Figure 5.9.1. Compound 9a upregulates p53, p21 and Bax levels in MCF-7 Human Breast Cancer Cells. Cells were treated 
with 20 µM for 24 hours, cells were lysed and total protein was collected and subjected to Western Blot Analysis to 
determine p53, p21 and Bax proteins expression levels in treated and non-treated control cells. β-actin was used as a 
loading control.  
 
 
MDM2 and Akt are negative regulators of p53 and the apoptotic process. Akt regulates cell survival, 
growth and glycogen metabolism, there are 3 isoforms of Akt; Akt1 which has a wide tissue 
distribution, Akt2 in muscles and adipose tissues and Akt3 in testes and brain. Akt is activated when 
growth hormones and cytokines bind to its receptor RTK. Mouse Double Minute 2 Homolog or 
MDM2 is a protein encoded by MDM2 gene and function as E3 ubiquitin ligase able to recognize the 
N-terminal of p53 and inhibits its transcriptional activation.  
 
To elucidate the role of Bcl-2, Akt and MDM-2 in the anti-tumor activity of compound 9a, MCF-7 
cells were treated with IC50 (20 µM) of compound 9a for 24 hours compared with untreated cells 
serving as a control. The lysates of both treated and untreated cells were prepared and processed for 
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western blot analysis to study the changes in the levels of Bcl-2, Akt and MDM-2 in order to evaluate 
the effects of compound 9a on these pathways. In this study, compound 9a inhibits the expression of 
Bcl-2, Akt and MDM-2 in MCF-7 treated cells compared to control.  
 
 
 
Figure 5.9.2. Compound 9a down-regulates Bcl-2, MDM-2 and Akt levels in MCF-7 Human Breast Cancer Cells. Cells 
were treated with 20 µM for 24 hours, cells were lysed and total protein was collected and subjected to Western Blot 
Analysis to determine Bcl-2, MDM-2 and AKT proteins epression levels in treated and non-treated control cells. β-actin 
was used as a loading control.  
 
Apoptosis execution pathway depends mainly of caspase 3, caspase 3 is a cysteine protease cleave 
ADP-ribose polymerase and activate SREPBs. Caspase 3 also activates other caspases such as 6, 7 and 
9. Caspase 3 is activated by pro caspase 3, therefore the pro form and the active form of caspase 3 
constitute a useful biomarker to confirm apoptosis.  
 
To elucidate the role of caspase 3 in the anti-tumor activity of compound 9a, MCF-7 cells were treated 
with IC50 (20 µM) of compound 9a for 24 hours compared with untreated cells serving as a control. 
The lysates of both treated and untreated cells were prepared and processed for western blot analysis 
to study the changes in the levels of pro-caspase 3 and caspase 3 in order to evaluate the effects of 
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compound 9a on these pathways. In this study, compound 9a up-regulated the expression of caspase 3 
in MCF-7 treated cells compared to control.  
 
Figure 5.9.3. Compound 9a u-regulate the levels of Caspase-3 in MCF-7 Cells. Cells were treated with 20 µM for 24 
hours, cells were lysed and total protein was collected and subjected to Western Blot Analysis to determine Pro-caspase 
and Caspase-3 proteins expression levels in treated and non-treated control cells. β-actin was used as a loading control.  
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6. Discussion:  
The discovery of novel chemotherapeutic analogs with improved safety profile for the treatment of 
cancer is highly warranted. Pyridine and its derivatives have occupied an important realm in synthetic 
organic chemistry due to their therapeutic and pharmaceutical properties. Pyridine derivatives have 
emerged as the backbone of over than 7,000 existing drugs, pyridine ring is an integral part of 
antimicrobial, anticancer and antiviral agents (Cocco et al., 2005). They have also emerged as potent 
anti-cancer agents, Epothilones with a nitrogen atom at ortho position and methyl substitution on 
pyridine ring exhibited anti-cancer activity against several cancer cell lines (Wang, 2005). 
Furthermore Heyakawa et al., was successful in synthesizing a series of pyridine derivatives with 
potent inhibition activity against tumor cells by inhibiting PI3K p110a (Heyakawa et al., 2000).   
 
In the present study, the effect of twenty novel pyridine derivatives were screened for their anti-cancer 
activity against different cell lines MCF-7, MDA-MB-231, HCT-116, SKOV-3 and OVCAR-3. To 
assess if their effect is cell or tumor type specific. Our data revealed that treating the above mentioned 
cancer cell lines with an initial concentration of 100µM for 24 hours suppressed the viability as 
follows: compound 9a reduced the viability by 40% in MCF-7 cells and by 45% in HCT-116, 
compound 7b reduced the viability in SKOV-3 by 35% and finally compound 11 suppressed the 
viability of MCF-7 by 44%.  
 
The initial screening of the novel pyridine derivatives indicated that these derivatives are selective in 
their anti-cancer activity, i.e. not tumor type specific nor generic agents but rather cell type specific. 
For instance, compound 9a was effective against MCF-7 cell lines but not MDA-MB-231 cell lines, 
despite the fact that both are adherent epithelial mammary cells derived from metastatic 
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adenocarcinoma. However, MCF-7 cell lines are responsive to hormone therapy, while MDA-MB-231 
is not and is more resistant to treatment and drug therapy than MCF-7. Guisado reported that 
Resveratrol, a chemotherapeutic agent is able to induce apoptosis in MCF-7 but failed to do so in 
MDA-MB-231. 
 
Furthermore, MCF-7 and MDA-MB-231 differ in the expression of p53 protein, MCF-7 exhibits the 
wild type p53 while MDA-MB-231 has a mutation in the arginine amino acid replaced by lysine at 
position 280 (Gurtner, 2010). This mutation renders the protein in MDA-MB-231 unstable, these cells 
also exhibit large amounts of phospholipase D which plays a role in the survival and sustention of the 
mutated p53 (Hui, 2006). Compound 9a was also effective against HCT-116 cell lines, expressing the 
wild type p53. In addition, compound 7b reduced the viability of SKOV-3 cell lines by 35%, however 
in OVCAR-3 cell line the viability was 100%, both SKOV-3 and OVCAR-3 are adherent ovarian 
epithelial cells derived from Caucasian female with adenocarcinoma. OVCAR-3 is a well-studied 
model of drug resistance in ovarian cancers (ATCC, 2014).  
 
Compound 9a was chosen to investigate the mechanism of action of this novel pyridine derivative 
against MCF-7 cell lines. The focus on MCF-7 was due to the dramatically increased number of breast 
cancer cases worldwide, breast cancer is the most frequently diagnosed cancer among women in about 
140 countries globally, representing one in four of all cancers in women. The incidence of breast 
cancer has increased intensely in developed countries, however the mortality rate is much higher in 
developing countries due to lack of early detection of the disease (Jemal et al., 2011).  In the State of 
Qatar specifically, breast cancer remains the top cause of death among women accounting for 36.3% 
of the total cases of cancer (Qatar Cancer Registry, 2014).  
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The study has revealed that compound 9a has anti-proliferative activity against MCF-7 cells with an 
IC50 of 20+/-0.268 µM. Previous researches in this field have supported the premise of using pyridine 
derivatives as anti-cancer agents against MCF-7 cell lines. Davari has published the anti-cancer 
activity of4-(1-benzyl-2-ethylthio-5-imidazolyl)-6-(4-bromophenyl0-2-imino-1,2-dihydropyridine-3-
carbonitrile against MCF-7 cells with an IC50 of 50.18+/- 1.11 µM (Davari et al., 2014). This anti-
proliferative activity against MCF-7 cells has also been detected by isatin-pyridine hybrid agents with 
IC50 of 6.3+/-0.79 (Eldehna et al, 2014).  
 
Studying the mechanism of which this novel derivative inhibits the proliferation of MCF-7 is central to 
build a conceptual framework at the cellular and molecular level assisting the rational approaches 
towards cancer treatment. Several pieces of evidences support that chemotherapeutic agents affect 
tumor cells through the biochemically regulated process of apoptosis or programmed cell death. This 
process received significant attention upon the discovery of inter-nucleosomal DNA breakdown that is 
different from necrosis. Apoptosis usually results in typical morphological and biochemical 
characteristics including condensation of the chromatin, shrinkage of the cytoplasm and blebbing of 
the plasma membrane.   
 
Apoptotic cells present several epitopes attracting macrophages and phagocytic cells and preventing 
secondary inflammation or the unfavorable initiation of inflammation. Harmlessly disposing of cancer 
cells is one of the main considerations in chemotherapy and consequently induction of apoptosis is an 
important strategy in anticancer drug research and development. Initially, in this study treating MCF-7 
cells with compound 9a for 24 hours resulted in observed apoptotic morphological features including 
the appearance of marked apoptotic bodies in concentration dependent manner.  
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The induction of apoptosis was further confirmed using Annexin-V Apoptotic Assay; a rapid and 
sensitive assay to detect different phases of apoptosis. The translocation of phosphatidylserine from 
the inner plasma membrane to the outer surface membrane is a sensitive way to detect cells 
undergoing apoptosis. Annexin-V conjugated to FITC binds phosphatidylserine on the cell surface; PI 
was used to detect cells in late apoptosis. The results of this assay indicated that approximately 46.8% 
of MCF-7 cells treated with IC50 “20 µM” of compound 9a for 24 hours are dying by the programmed 
cell death “apoptosis”, 46.8% of the total population represented cells in early apoptosis, late apoptosis 
and death stage.  
 
Testing the cytotoxicity of any chemotherapeutic agent on non-tumorigenic cells is an essential step in 
assessing the effectiveness of this novel chemotherapeutic agent, in this study the cytotoxicity of 
compound 9a was examined and compared in both MCF-7 cells and MCF-12a cell lines after treating 
the cells with IC50 of 20µM for 24hours. 
 
MCF-12a cell lines are adherent epithelial mammary cells derived from 60 years old Caucasian 
female. Statistical analysis using non-parametric methods “Mann-Whitney Test” of the obtained 
viability % for both cells indicated that compound 9a is less toxic towards MCF-12a with a statistical 
significance of 0.001.  
 
The cell cycle checkpoints analysis of MCF-7 cells treated with 20 µM of compound 9a for 24 hours 
did not reveal any significant changes when compared with the untreated MCF-7 cells. However, a 
slight increase in G1 phase of about 9% was indicated. Arresting the treated cell in different 
checkpoints is highly correlated to the amount of p21 protein; this correlation was demonstrated in a 
study of colon cancer cell lines. Treating colon cancer cells harboring the wild-type p21 with ɤ- 
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irradiation underwent cell cycle arrest, while cells lacking p21 were unsuccessful in arresting and 
instead proceeded to apoptosis (Manish, 2001). The study of p21 expression by Western blot indicated 
a slight change in the expression level of this protein, which may explain arresting MCF-7 cells in G1 
phase.  
 
In order to investigate the molecular pathway of compound 9a, the expression of various essential 
proteins in cell cycle and apoptosis have been studied using Western blot analysis. The obtained data 
indicated that compound 9a up-regulated p53 in MCF-7 cells treated with 20 µM for 24 hours. p53 the 
tumor suppressor protein plays an essential role in both regulating the cell cycle arrest and inducing 
apoptosis, cell lines harboring a mutation in p53 are resistant to most chemotherapeutic agents as 
indicated earlier in MDA-MB-231 cell line. Another study has revealed that neoplastic cells acquired 
different mutations including a mutation in p53 are highly resistant to apoptosis (Manish, 2001). MCF-
7 cells express the wild type p53 and therefore have the capability to undergo programmed cell death 
and cell cycle growth arrest. p53 is the most studied tumor suppressor and can apparently be activated 
by different chemotherapeutic agents including pyridine derivatives.  
 
Oren and his coworkers were the first to investigate the role of p53 in controlling apoptosis upon 
transfecting myeloid leukemia deficient cells with wild type p53 (Yonish et al., 1991).  
 
Later on, several pieces of evidence supported the role of p53 as a major regulator of programmed cell 
death using p53 knockdown thymocytes (Clarke et al., 1993). Interestingly, p53 has also been shown 
to contribute to chemotherapy-induced cell death, on the other hand loss of p53 is a major cause of 
chemotherapy resistant (Lowe et al., 1993). Up-regulation of p53 activates the apoptotic pathway by 
controlling several pro-apoptotic proteins of the Bcl-2 family including Bax.  
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Bax acts as a down-stream regulator to initiate apoptosis, several studies have indicated that the 
disruption of Bax level in HCT116 cells results in defect in the apoptotic pathway (Zhang et al, 2000). 
Our current data has revealed that compound 9a can significantly up-regulates Bax expression and 
thus initiates the apoptotic pathway.  
 
Furthermore, the effect of this potent pyridine derivative compound has also been investigated for 
important anti-apoptotic proteins such as Bcl-2. Bcl-2 is a strong anti-apoptotic signaling protein of the 
Bcl-2 family that has been significantly down-regulated in MCF-7 cells upon treatment with 
compound 9a 20µM for 24hours. Bcl-2 binds to Apaf-1 and thus inhibits the activation of the caspases 
and execution of the cell, however when the levels of Bax increase, the binding will be disturbed 
allowing the activation of the apoptotic pathway.  
 
Mdm-2 has also been down-regulated by compound 9a, Mdm-2 is the mouse double minute 2 protein 
regulated by Mdm-2 gene and was originally discovered in fibroblast 3T3 cells. Mdm-2 is highly 
associated with p53 and evidence has shown that this protein is capable of controlling the tumor 
suppressor p53 in the cell. Both proteins are linked to each other by the negative feedback loop that 
aims to regulate the expression level of p53 and thus protecting species from excess apoptosis and 
neurodegenerative diseases (Ute .M, 2003).  
 
Mdm-2 is an E3-ubiquitin ligase that inhibits p53 by mainly two mechanisms, by binding to the 
transactivation domain in p53 thus inhibiting p53-dependent transcription, or by the ubiquitination of 
p53 and targeting it to proteasome degradation. Induction of p53 and inhibition of Mdm-2 relationship 
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in the cell will result in the accumulation of p53 and the activation of the apoptotic pathway. Mdm-2 
has recently becomes a focus for much research and a target of many cancer therapies (Fulda, 2015).  
 
Compound 9a has also down-regulated the expression of Akt protein (protein-kinase B) in MCF-7 
cells after 24hour treatment, the serine-threonine kinase plays an essential role in various cellular 
processes including apoptosis and cell survival and proliferation (Ute .M, 2003).  
 
In order to investigate whether compound 9a induces caspase-dependent or independent cascade we 
have also studied the expression of caspase-3. Caspase-3 is an essential member of the cysteine-
aspartic acid protease encoded by Casp3 gene and plays a vital role in the execution of cells undergo 
apoptosis. Caspase-3 exists in an inactive form called “pro-caspase-3” which undergoes proteolytic 
processes at specific aspartic residues to generate the large and small domains forming the active 
enzyme. Caspase-3 can be activated it by different caspases 8, 9 and 10. The results of the current 
study has revealed that compound 9a up-regulates the expression of Caspase-3 in MCF-7 cells treated 
for 24 hours with the IC50 of 20 µM, which indicates that compound 9a induces apoptosis in MCF-7 
cells through the caspase-dependent cascade (Fulda, 2015). 
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6.1. Diagram of Discussion:  
 
 
 
Figure 6.1. Summary of Impact of 9a on MCF-7 cells.  Compound 9a induced apoptosis by up-regulating the expression 
levels of p53, Bax and Caspase-3 and down-regulating Bcl-2, Akt and Mdm-2 proteins. Compound 9a slightly arrested 
MCF-7 cells in G1 phase correlated with the slight increase in the expression of p21.  
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7. Conclusion and Recommendation: 
 
Discovering novel chemotherapeutic agents with improved safety profile and less toxicity to non-
tumorigenic cells is highly warranted due to the dramatically increasing cancer incidence and 
mortality. Pyridine derivatives have proven to be potent and effective agents in treating different types 
of cancer. In the present study, compound 9a revealed anti-proliferation activity against MCF-7 cells 
and resulted in the induction of apoptosis. Compound 9a up-regulated the expression of p53, Bax and 
Caspase-3 proteins and down-regulated the following proteins: Bcl-2, Mdm-2 and Akt. Compound 9a 
exhibited less toxicity on non-tumorigenic breast epithelial cells MCF-12a with a statistical 
significance of p value < 0.05.  
 
Findings of this study indicated that compound 9a possessed anti-proliferative activity against MCF-7 
cells and may be a promising chemotherapeutic agent with less toxicity to non-tumorigenic breast 
epithelial cells MCF-12a. However, screening novel derivatives on other cancer cell lines is highly 
required. In addition, mechanistic examinations are also necessary to evaluate the exact role of 
compound 9a against MCF-7 cells. In-vivo studies are necessary to investigate the mechanism and 
impact of 9a on physiological processes.  
 
Although the aims of the study were addressed, there were a few limitations to the study. Assessment 
of ploidy and doubling time of used cell lines were not conducted due to time limitation. More 
mechanistic investigations are necessary to evaluate the exact molecular mechanism of compound 9a. 
Finally, screening in different cancer cell lines and their non-tumorigenic counterparts is essential; 
however the present research is limited with the available cell lines.   
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 اكتشاف مركبات جديدة من مجموعة مركبات البيريدين لعلاج اورام السرطان
 ملخص البحث
ان المسبب الثاني للوفيات عالميا حيث تشير احصائيات المنظمة العالمية لأبحاث السرطان أن خطر يعتبر السرط خلفية البحث:
 8مليون حالة جديدة وما يقارب  41حيث وصلت الاحصائيات لما يقارب  2102الإصابة بمرض السرطان ازداد دراماتيكيا في عام 
م، وتعود هذه  5302مليون في عام  42و 5202مليون حالة في عام  91مليون حالة وفاة. ويتوقع زيادة هذه النسب الى ما يقارب 
من مجمل الوفيات،  %01التوقعات الى الزيادة المتوقعة في نسبة الأعمار بين الشعوب.  كما تمثل حالات السرطان في دولة قطر 
. وعليه، تتسم 0302درجة عالية في عام وتعتبر هذه النسبة عالية نسبيا بالنسبة لمرض منفرد، كما ويتوقع أن يتضاعف هذا العدد ب
الحاجة الى اكتشاف علاجات جديدة من شأنها المساهمة في علاج هذا المرض الخبيث ولتحسين نوعية العلاجات المتوفرة. لقد حظيت 
ائية، وتمثل مركبات البريدين بشهرة واسعة في مجال الكيمياء العضوية لما أثبتته من فعالية كمركبات ذات خصائص علاجية وكيمي
 حلقة البريدين حلقة أساسية في العديد من المركبات المستخدمة ضد مختلف الأحياء الدقيقة والفيروسات والاورام المختلفة.
 enidiryPفي بحثنا الحالي فقد قمنا بدراسة مفصلة لعشرين مركب جديد من فصيلة مركبات البيريدين  التجارب العملية: 
نوع من الخلايا السرطانية ومنها (سرطان الثدي، سرطان الرحم وسرطان القولون) لمعرفة تأثير هذه  على أكثر من sevitavireD
أ باعتباره 9المركبات ان كان عاما ضد مختلف أنواع السرطانات أم ذا تأثير معين.  وتم دراسة التركيز التثبيطي النسبي للمركب 
 CTIF V-nixennAة الموت المبرمج للخلايا عن طريق تجارب معينة مثل مركب فعال ضد خلايا الثدي السرطانية، كما تم دراس
أ عن طريق 9. كما تمت دراسة المسار الجزيئي للخلايا بعد معالجتها بمركب yrtemotyC wolFومراحل دورة الخليه باستخدام 
 ، بالإضافة الى دراسة تأثير المركب على الخلايا الطبيعية للثدي.olB nretseWاستخدام 
ساعة  42ومعالجة مختلف الخلايا السرطانية لمدة  Mµ001أوضحت الدراسة على مركبات البيريدين عند استخدام تركيز  لنتائج:ا
، كما يقوم %54بنسبة   611-TCHوخلايا  %04بما يعادل  7-FCMأ يثبط خلايا 9مركبات فعاله كما يلي: المركب  4وجود 
. وقد تركزت التجارب اللاحقة %44يقوم يتثبيط ذات الخلايا بنسبة  11ومركب  %53بنسبة  3-VOKSب بتثبيط خلايا 7المركب 
أ يعمل من خلال تحفيز الخلايا على الموت المبرمج بتركيز تثبيطي نسبي يعادل 9أ حيث أثبتت التجارب أن مركب 9على مركب 
بعد علاجها بالمركب لما  7-FCMلايا في خ 3-esapsaC dna xaB ,35pأ بزيادة تركيز البروتين 9. كما قام المركب Mµ02
. أخيرا فقد أثبتت التجاربة أن التأثيرات tkA dna 2-mdM ,2-lcBساعة، وفي المقابل قام ذات المركب بتثبيط البروتينات  42يعادل 
 السمية على خلايا الثدي الطبيعية كانت أقل عند مقارنتها احصائيا بالخلايا السرطانية. 
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وبالتالي قد  7-FCMأ يمثل مركبا فعالا ذا تأثيرات تثبيطية للخلايا السرطانية 9نتائج النهائية للبحث أن مركب تدل ال حصيلة البحث:
يمثل مركبا مهما ذا تأثير أقل على الخلايا الطبيعية وبالتالي تجبن التأثيرات الجانبية العلاجات الكيمائية. ومن الضروري استكمال 
المركب لمعرفة تأثيره على أنواع أخرى من الخلايا السرطانية ولمعرفة كيفية عمل هذا المركب الفعال وطريقة الأبحاث على هذا 
 ، بالإضافة الى ضرورة عمل دراسات على الفئران. FCM-7تثبيطه للخلايا 
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 للبحث العربي الموجز
 من مجموعة مركبات البيريدين لعلاج اورام السرطانموضوع البحث: اكتشاف مركبات جديدة 
 
 مقدمة البحث:
يعتبر السرطان المسبب الثاني للوفيات عالميا حيث تشير احصائيات المنظمة العالمية لأبحاث السرطان أن خطر الإصابة بمرض 
كما تمثل حالات السرطان في دولة مليون حالة.  41حيث وصلت الاحصائيات لما يقارب  2102السرطان ازداد دراماتيكيا في عام 
من مجمل الوفيات، وتعتبر هذه النسبة عالية نسبيا بالنسبة لمرض منفرد، كما ويتوقع أن يتضاعف هذا العدد بدرجة عالية  %01قطر 
لشهيرة " . وقد حظيت أبحاث السرطان في دولة قطر برعاية سمو الشيخة موزة بنت ناصر المسند انطلاقا من مقولتها ا0302في عام 
إن محاربة السرطان تعد سبباً رئيساً في توحد المجتمعات بكافة المناطق حول العالم وقد تكون قطر دولة صغيرة من حيث عدد 
السكان، لكن لدى مجتمعها رغبة كبيرة في أن تلعب دوراً ريادياً في مجال البحث وتطوير العلاجات واستحداث أشكال جديدة للرعاية 
 ى جاهدين لتحقيق أفضل النتائج لدى مرضى السرطان ومن يهتم برعايتهم.". الصحية، لذا نسع
 
 الهدف من البحث:
، تتسم الحاجة الى اكتشاف علاجات جديدة من شأنها المساهمة في علاج هذا المرض الخبيث، وفي بحثنا الحالي فقد استنادا الى ما تقدم
على أكثر من نوع من الخلايا  sevitavireD enidiryPت البيريدين قمنا بدراسة مفصلة لعشرين مركب جديد من فصيلة مركبا
السرطانية ومنها (سرطان الثدي، سرطان الرحم وسرطان القولون) لمعرفة تأثير هذه المركبات ان كان عاما ضد مختلف أنواع 
أنواع الخلايا السرطانية سابقة على كافة  001Mµ حيث تم فحص العشرين مركب بتركيز أولي يبلغ السرطانات أم ذا تأثير معين. 
. ومن ثم دراسة المركبات الفعالة فقط %05الذكر، ومن ثم انتقاء المركبات الاكثر فعالية والتي تثبط الخلايا السرطانية بما يعادل 
 لمعرفة طريقة عملها على المستوى البيولوجي للخلايا. 
 
 الاختبارات العملية:
وجود أربعة مركبات فعالة ضد مختلف الخلايا السرطانية كما  Mµ001مركبات العشرين بتركيز لقد أثبتت نتائج الفحص الأولية لل
أ أثبت فعاليته ضد 9وهي نوع من أنواع سرطانات الرحم، مركب  %53بنسبة  3-VOKSب اثبت فعاليته ضد خلايا 7يلي: مركب 
أثبت أيضا فعاليته ضد خلايا  11أخيرا المركب ، و%54وخلايا سرطان الكبد بنسبة  %04بنسبة  7-FCMخلايا سرطان الثدي 
 . %44ب ولكن بنسبة أقل تعادل 7كما الحال لدى المركب  3-VOKS
 
 كما يلي: 7-FCMأ لعدة تجارب والتي تبين الطريقة البيولوجية لعمل هذا المركب على خلايا 9ومن ثم قمنا باختيار المركب 
 
 أ:9ة التثبيط التركيزي النصفي للمركب وقياس قيم 7-FCMالتغيرات الشكلية في خلايا  
) وملاحظة التغييرات Mµ 001 – 05 – 02 – 5 – 1 – 5.0أ ( 9بتركيزات مختلفة تدريجية من المركب  7-FCMتم علاج خلايا 
لخلايا تتغير ) بينما بدأت اMµ 5 – 1 – 5.0الشكلية للخلايا، لم تظهر أية تغييرات الشكلية على الخلايا عند المعالجة بالتركيزات (
. وتتمثل هذه التغييرات  Mµ 02شكليا الى ما يسمى الموت المبرمج للخلايا (أو الموت المقدر) عند التركيزات الأعلى ابتداء من 
، تغير النواه تغير دراماتيكي متمثل في تكثف الكروماتين، كما sbelbالشكلية بما يلي: انكماش الخلايا وظهور فقاعات او ما يسمى 
هذه الخلايا بالعضيات الداخلية، وأكثر ما يميز هذا النوع من موت الخلايا أنه يتم التهامها من قبل أنواع مختلفة من الخلايا  تحتفظ
أ برسم العلاقة 9المناعية أو الخلايا المجاورة دون استثارة الجهاز المناعي في الجسم.  كما تم قياس التركيز التثبيطي النصفي للمركب 
 . Mu02ن النسبة المئوية للتثبيط والتركيز المثبط للنمو، وعليه فقد تم احتساب التركيز التثبيطي النصفي بما يقارب البيانية بي
 
 أ:9بالمركب  7-FCMدراسة الموت المبرمج للخلايا عند معالجة خلايا سرطان الثدي  
للخلايا فقد قمنا باجراء ما يسمى (فحص الموت  عن طريق الموت المبرمج 7-FCMأ يثبط الخلايا السرطانية 9ولتأكيد أن المركب 
والتي تتمثل أساسا في تغير  7-FCM) لدراسة التغييرات التي تطرأ على الغشاء الخلوي لخلايا CTIF V-nixennAالمبرمج للخلايا 
هم في الموت المبرمج من الطبقة الداخلية للغشاء الى الطبقة الخارجية. ويعد هذا التغيير حدث م SP enireslyditahpsohpموقع 
وبالتالي تتبع الخلايا التي  SPبالارتباط بالدهون الفسفورية  CTIFوالذي يرتبط بالمركب  V-nixennAللخلايا، وعليه يقوم المركب 
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قد خضعت للموت المبرمج بعد علاجها  7-FCMمن خلايا  %4.84تخضع للموت المبرمج. وقد اثبتت التجارب أن ما يقارب من 
 ساعة.  42لما يقارب  02أ  بتركيز Mµ9بالمركب 
 
 :7-FCMأ على مراحل انقسام الخلايا ومراقبة الجودة في خلايا 9دراسة تأثير المركب  
ومراقبة الجودة ، الا أن نتائج البحث لم تظهر تغييرات جوهرية  7-FCMأ على مراحل انقسام الخلايا 9كما تم دراسة تأثير المركب 
ساعة. ومن خلال الاطلاع على  42لما يقارب  02عند معالجتها تركيز  7-FCMى مراحل انقسام الخلايا أ عل9تثبت تأثير المركب 
العديد من الأبحاث السابقة في هذا المجال فان من صفات بعض المركبات ذات التاثير الكيماوي على الخلايا السرطانية أن تقوم بالتأثير 
موت المبرمج معا، الا أن بعض المركبات تثبط الخلايا السرطانية باتباع احدى هذه الطرق على مراحل نمو هذه الخلايا و دفعها الى ال
  )Mµ 05(أ 9فقط وليس كليهما. ولتكيد هذه المعلومة فقد قمنا بإعادة التجربة المذكورة باستخدام تركيز أعلى من المركب 
 
 :7-FCMأ على المسار الجزيئي في خلايا 9دراسة تأثير المركب  
لما يقارب  Mµ02بتركيز  7-FCMأ فقد قمنا بدراسة مفصلة للمسار الجزيئي بعد معالجة خلايا 9ا في دراسة كيفية عمل المركب تعمق
والتي تلعب دورا مهما  3-esapsaC dna xaB ,35pساعة. وقد أوضحت النتائج زيادة ذات دلالة إحصائية في البروتينات التالية  42
لخلايا، كما لوحظ وجود انخفاض واضح في البروتينات المثبطة للموت المبرمج للخلايا ما يسمى واساسيا في الموت المبرمج ل
. وكذا كان التأثير 35pالتي تلعب دورا حيويا في ابطال مفعول بروتين  2-mdM، كما تم تثبيط بروتينات أخرى منها   2-lcBزمرة
فلم توضح النتائج ما يثبت زيادة  12pلخلايا ونموها. أما بالنسبة لبروتين والذي يلعب دورا فعالا في زيادة انقسام ا tkAعلى بروتين 
 .7-FCMأ على دورة انقسام الخلايا 9معدلها وهذا يتوافق مع النتائج السابقة والدالة على عدم تأثير المركب 
 
 : النتائج
ة مختلفة مما يبين أن تأثير هذه المركبات هو أوضحت الدراسات على مركبات البيريدين وجود أربع مركبات فعالة ضد خلايا سرطاني
أ لفعاليته ضد خلايا 9محدد لنوع الخلايا السرطانية وليس مركب عام لعلاج جميع أنواع الأورام السرطانية. وقد تمت دراسة المركب 
 ANDخلال تجزئة  أ له تأثير مضاد لنمو هذه الخلايا من9، ولقد أوضحت الدراسة المعملية أن المركب 7-FCMسرطان الثدي 
وتحفيز الخلايا للموت المبرمج أو الموت الاضطراري، وتم تأكيد هذه النتائج بعمل اختبارات أخرى تؤكد هذا التأثير ومنها فحص 
ودراسة المسار الجزيئي والتحليل الكمي لمستوى بروتينات متعددة. وقد تبين أن  V-nixennAالموت المبرمج للخلايا باستخدام 
والتي تلعب دورا أساسيا في الموت المبرمج  3- esapsac & xaB ,35pيقوم بزيادة ذا دلالة إحصائية للبروتينات  أ9المركب 
البروتين المضاد لموت الخلايا. بالإضافة الى خفض مستوى بعض  2-lcBللخلايا، في حين يقوم ذات المركب بخفض مستوى 
 . tkA & 2-mdMالبروتينات الأخرى مثل 
 
 ث:محصلة البح
، ويعمل هذا المركب من خلال تحفيز الموت  7-FCMأ له تأثير مضاد لسرطان الثدي نوع 9نستنتج من هذه الدراسة أن مركب 
، تتبع  CI05المبرمج لهذه الخلايا تتمثل في عدة دلالات منها: التغيرات المورفلوجية في شك الخلايا بعد علاجها بالمركب بتركيز 
الغشاء البلازمي لهذه الخلايا بعد العلاج وأخيرا من خلال دراسة المسار الجزيئي والذي أوضح زيادة التغيرات الفسيولوجية في 
وخفض معدلات البروتينات  3-esapsaC dna xaB ,35pمعدلات البروتينات الأساسية في هذا النوع من الموت المبرمج مثل 
انخفاضا واضحا يتوافق مع الزيادة المطردة للبروتين  2-mdMن . كما أوضح التحليل الكمي لمستوى البروتي2-lcBالمثبطة مثل 
والذي يلعب دورا حيويا في نشاط الخلايا السرطانية وزيادة سرعة انتشارها. لم تبين  tkA. هذا إضافة الى خفض مستوى بروتين 35p
، وهذا 12pه من خلال دراسة مستوى بروتين أ وهو ما تم تأكيد9تجارب دراسة مراحل انقسام الخلية ومتابعة الجودة أي تأثير للمركب 
 من خلال الموت المبرمج للخلايا وليس بالتأثير على دورة انقسام الخلية. 7-FCMأ يثبط خلايا 9يؤكد أن المركب 
 
 التوصيات:
لمعرفة تأثير هذا يتوجب مستقبلا عمل دراسات أخرى على أنواع مختلفة من الخلايا السرطانية مثل خلايا سرطان الرئة والجلد والدم 
-TCHالمركب عليها، كما يتوجب دراسة تأثيره أيضا على خلايا الكبد السرطانية حيث اثبتت التجارب الأولية فعاليته بتثبيط خلايا 
أ على 9. كما يتوجب عمل دراسات معينه على الجرذان لمعرفة تأثير المركب 35pوالتي تحتوي على البروتين  %54بنسبة  611
 داخلية. الأورام ال
 
